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SUMMARY 
The fundamental principle of immunity is self and non-self discrimination. To do so, 
innate immune cells express pattern recognition receptors (PRRs) that recognize 
foreign pathogen associated molecular patterns (PAMPs) and endogenous danger 
associated molecular patterns (DAMPs). ARTD1, the major nuclear enzyme 
catalyzing the post-translational modification ADP-ribosylation, has been reported to 
enhance PRR-induced proinflammatory gene expression as a transcriptional co-factor 
of NF-κB in cultured cells. The cell type specific ARTD1 contributions in vivo as well 
as the contribution of other ADP-ribosylating enzymes during inflammation are 
currently under investigation. 
 The main aim of this study was to comprehensively determine the function of 
ARTD1 specifically in macrophages in vivo. In addition, we investigated in which cell 
type ADP-ribosylation inhibitors affect LPS-induced proinflammatory signaling. 
Finally, we analyzed all ARTD family members and their function during LPS-
proinflammatory signaling in fibroblasts. 
 RNA sequencing of LPS/IFN-γ stimulated bone marrow derived macrophages 
(BMDM) identified Il12b expression to be significantly reduced in Artd1 knock-out 
BMDMs as compared to wild-type controls. To confirm the relevance of reduced 
Il12b levels during Th1 immune responses in vivo, we generated a myeloid cell 
specific Artd1 knock-out strain (Artd1ΔMyel) and tested three inflammatory models: i) a 
systemic LPS-induced inflammation, ii) a local gastric Helicobacter pylori infection 
and iii) a subcutaneous MC-38 tumor xenograft model. In all three tested models, we 
observed using Artd1ΔMyel mice reduced lymphocyte activation due to decreased IFN-γ 
expression. We observed a decreased NK cell activation during sepsis and decreased 
CD4 and CD8 T cell activation during Helicobacter pylori infection as well as the 
MC-38 tumor xenograft model. Moreover, co-treatment of wild-type mice with LPS 
and ADP-ribosylation inhibitors (i.e. PARPi) reduced the serum levels of the 
quantified cytokines (e.g. IFN-γ or TNF-α), and co-treatment of splenocytes from the 
same mice revealed the same effect. Interestingly, the activation of NK cells, the 
major IFN-γ producer during sepsis with IL-18, was inhibited by PARPi. 
Furthermore, a siRNA screen targeting every individual ARTD family member 
revealed ARTD11 to selectively enhance Cxcl10 and Cxcl2 gene expression in 
fibroblasts but not in macrophages during LPS-signaling.  
 Together these data provide strong evidence that ARTD1 controls the Th1 
immune response in macrophages via the IL-12/18-IFN-γ axis. Moreover, we 
identified IL-18 simulated NK cells to be sensitive to PARPi treatment and ARTD11 
as a potential interesting ARTD family member to influence proinflammatory gene 
expression in fibroblasts. Thus, ADP-ribosylation catalyzing enzymes differently 
promote proinflammatory cytokine expression in several cell types, strongly 
suggesting clinical significance. Future investigations of ADP-ribosylation functions 
in vivo require an ARTD family and cell type specific approach. 
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ZUSAMMENFASSUNG 
Das Grundprinzip der Immunität ist Selbst- und Nicht-Selbstdiskriminierung. Dazu 
exprimieren angeborene Immunzellen Mustererkennungsrezeptoren (PRRs), die fremde 
pathogenassoziierte molekulare Muster und endogene gefahrassoziierte molekulare 
Muster erkennen. ARTD1, das wichtigste nukleare Enzym, das die posttranslationale 
Modifikation ADP-Ribosylierung katalysiert, steigert die PRR-induzierte 
proinflammatorische Genexpression als transkriptioneller Co-Faktor von NF-κB in 
kultivierten Zellen. Die zelltypspezifischen ARTD1-Beiträge in vivo sowie der Beitrag 
anderer ADP-ribosylierender Enzyme während Entzündungen werden derzeit untersucht.  
Das Hauptziel dieser Studie war die umfassende Bestimmung der Funktion von 
ARTD1 speziell in Makrophagen in vivo. Darüber hinaus haben wir untersucht, in 
welchen Zelltypen ADP-Ribosylierungsinhibitoren die LPS-induzierte 
proinflammatorische Signalübertragung beeinflussen. Schließlich analysierten wir alle 
ARTD-Familienmitglieder und ihre Funktion während der LPS-proinflammatorischen 
Signalübertragung in Fibroblasten.  
Die RNA-Sequenzierung von LPS/IFN-γ stimulierten Knochenmark-
Makrophagen (BMDM) ergab, dass die Il12b-Expression in Artd1-defizienten BMDMs 
im Vergleich zu Wildtyp-Kontrollen signifikant reduziert war. Um die Relevanz 
reduzierter Il12b-Spiegel während der Th1-Immunreaktionen in vivo zu bestätigen, haben 
wir einen myeloischen zellspezifischen Artd1-Knock-out-Stamm (Artd1ΔMyel) generiert 
und drei Entzündungsmodelle getestet: i) eine systemische LPS-induzierte Entzündung, 
ii) eine lokale gastrische Helicobacter pylori-Infektion und iii) ein subkutanes MC-38-
Tumormodell. In allen drei getesteten Modellen beobachteten wir in Artd1ΔMyel Mäusen 
eine reduzierte Lymphozytenaktivierung basierend auf einer verminderten IFN-γ-
Expression. Wir beobachteten eine verminderte NK-Zellaktivierung während der Sepsis 
und eine verminderte CD4- und CD8-T-Zellaktivierung während der Helicobacter pylori-
Infektion sowie während des MC-38-Tumormodells. Außerdem reduzierte die Co-
Behandlung von Wildtyp-Mäusen mit LPS- und ADP-Ribosylierungsinhibitoren (z.B. 
PARPi) die Serumspiegel einiger quantifizierter Zytokine (z.B. IFN-γ oder TNF-α), und 
die Co-Behandlung von Milzzellen derselben Mäuse zeigte den gleichen Effekt. 
Interessanterweise wurde die Stimulation von NK-Zellen, den wichtigsten Produzenten 
von IFN-γ nach LPS-Stimulation, mit IL18 durch PARPi gehemmt. Zudem identifizierten 
wir mittels einer siRNA-Screen aller ARTD-Familienmitglieder, dass ARTD11 die LPS-
induzierte Cxcl10 und Cxcl2 Genexpression in Fibroblasten, aber nicht in Makrophagen, 
selektiv steigerte. 
Zusammengenommen liefern diese Daten starke Hinweise darauf, dass ARTD1 in 
Makrophagen die Th1-Immunantwort über die IL-12/18-IFN-γ-Achse steuert. Darüber 
hinaus identifizierten wir IL-18 simulierte NK-Zellen als empfindlich für die PARPi-
Behandlung und ARTD11 als potenziell interessantes ARTD-Familienmitglied, um die 
proinflammatorische Genexpression in Fibroblasten zu beeinflussen. So fördern ADP-
Ribosylierung katalysierende Enzyme unterschiedlich die proinflammatorische 
Zytokinexpression in verschiedenen Zelltypen, was auf eine starke klinische Bedeutung 
hindeutet. Zukünftige Untersuchungen von ADP-Ribosylierungsfunktionen in vivo 
erfordern eine ARTD-Familien und einen zelltypspezifischen Ansatz. 
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INTRODUCTION 
1. ADP-ribosylation 
ADP-ribosylation is an evolutionary conserved post translational modification (PTM) that is 
present in many prokaryotic and all eukaryotic cells, except for yeast1. The PTM is catalyzed 
by ADP-ribosyltransferases (ARTs) that covalently attach ADP-ribose (ADPr) to amino acid 
residues of target proteins using nicotinamide adenine dinucleotide (NAD+) as substrate. 
Bacterial toxins such as diphteriae2, cholerae3, pertussis4 or clostridia toxins5 mono-ADP-
ribosylate host proteins to inhibit their function and promote bacterial pathogenesis6. Beside 
prokaryotic ARTs, various eukaryotic proteins have been described to catalyze, hence “write” 
ADP-ribosylation7. Based on structural homologies to bacterial toxins the writers have been 
classified into two groups: Intracellular diphtheria toxin-like ARTs (ARTDs, formerly known 
as PARPs8) and the ectopic cholera toxin-like ARTs (ARTCs9). Additionally, Sirtuins 
(specifically SIRT410 and SIRT611) are also considered to possess ADP-ribosylating activity. 
While all of the known ARTs attach a single ADPr molecule to a protein, which is called 
mono-ADP-ribosylation or MARylation, only few ARTs can further modify the initial ADPr 
with additional ADP-ribose molecules generating linear or branched chains which is called 
poly-ADP-ribosylation or PARylation12. 
 Genome wide sequence analysis identified 18 intracellular eukaryotic ARTDs that 
share a common “PARP signature” motif in their C-terminal ART domain13 and localize to 
various intracellular compartments (Figure 1)14. While four members (ARTD1, 2, 5, 6) 
catalyze PARylation, twelve members (ARTD3, 4, 8, 10, 11, 12, 14, 15, 16, 17 and 18) 
catalyze MARylation. For two of them, ARTD9 and ARTD13, no enzymatic activity has 
been described so far15. Furthermore, numerous proteins possess ADP-ribose interaction 
domains and are considered as “readers” of ADP-ribosylation1,16 (Figure 1). Another set of 
enzymes including the PAR-degrading enzyme poly (ADP-ribose) glycohydrolase (PARG) 
hydrolase “erase” ADP-ribosylation (Figure 1) on target proteins making ADP-ribosylation a 
fully reversible PTM1,7.  
 Protein ADP-ribosylation can either affect the enzymatic activity of the modified 
protein or their interaction with nucleic acids and with other proteins12. Similar to other post-
translational modifications such as acetylation, phosphorylation, ubiquitination, sumoylation 
or methylation, protein ADP-ribosylation is implicated in a plethora of different cellular 
processes including genomic stability, transcriptional control, energy metabolism and cell 
death17-20. 
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Figure 1. Overview of the writers, readers and erasers of ADP-ribosylation. Enzymatic activity 
and cellular localization (nuclear (N) or cytoplasmic (C)). Adapted from Hottiger (2015)7. 
2. ADP-ribosylation induced cell death and the release of danger associated molecular 
patterns (DAMPs) 
The macroscopic hallmarks of inflammation include swelling, heat, redness, pain and/or loss 
of function21. On the cellular and molecular level, inflammation is a process that is initiated 
by tissue damage (sterile inflammation) or microbial infections22 and is regulated in a very 
complex, cell-type and stimulus dependent manner23. Tissue damage or cell death can be 
initiated in a regulated manner (i.e. apoptosis or necrosis) or by cell injury. While apoptotic 
cell death does not induce an inflammatory response, the necrotic cell death does so due to the 
release of DAMPs or alarmins (see below)24. 
 The constant exposure of cells to genotoxic sources, such as UV light, reactive 
oxygen species or alkylating agents induces and requires PARylation to maintain genome 
integrity25,26. It is very well documented that ARTD1, ARTD2 and to a lower extent also 
ARTD3 recognize and bind to single- and double strand breaks but also abnormal DNA 
structures, leading to activation and PAR formation27-32. PARylation marks the sites of DNA 
damage and facilitates DNA repair to restore cellular homeostasis25. While adequate DNA 
repair promotes cell survival and lowers the risk of oncogenic transformations, inhibition of 
PARylation, knock-out or knock-down of ARTD1 sensitizes cells to DNA-damaging agents33. 
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Figure 2. ARTD1 activation is a proxy for cell stress. Genotoxic stress levels correlate with ARTD1 
activation. Whereas basal PARylation is beneficial for the host during the DNA damage response, 
ARTD1 hyperactivation drives cells into necrosis. Figure taken from Luo et al 201234 
 
 Increasing genotoxic stress levels correlate with increasing ARTD1 activity, 
ultimately resulting in ARTD1 hyper-activation (Figure 2). The fact that ARTD1 cleavage 
was among the first identified caspase “death substrates”, suggested a regulatory role during 
apoptosis35. However, pharmacologic inhibition or generation of a knock-in mouse expressing 
a non-cleavable ARTD1 did neither influence cellular susceptibility nor the processing of the 
apoptotic program itself, indicating that caspase-mediated cleavage of ARTD1 and 
subsequent inhibition of its enzymatic activity has another physiological role36,37. DNA 
fragmentation is a hallmark of apoptosis, which would lead to ARTD1 hyper activation and 
energy expenditure. Thus, ARTD1 cleavage during apoptosis excludes its activation and 
preserves energy for ATP sensitive steps during apoptosis36,38.  
 In contrast to ARTD1’s passive role during apoptosis, PARylation actively influences 
cell fate during necrosis. Hyper-activated ARTD1 (i.e. by DNA damage) may cause regulated 
necrosis via distinct pathways. Extensive PARylation decreases cellular NAD+ levels up to 
20% in 5-15 mins and is considered as the main NAD+ catabolizing process in the cell39-41. To 
balance decreased NAD+ levels the cells activate adenosine triphosphate (ATP)-dependent 
salvage pathways resulting in ATP depletion and an comprised metabolic state of the cell42. 
Emerging concepts describe ARTD1 as a proxy/sensor for cellular stress levels and 
PARylation as critical determinant of cell fate34,36,43. Depending on the severity and duration 
of stress, cells exhibit different ways to limit cell and subsequent tissue damage, ranging from 
senescence via apoptosis to necrosis. Massive genotoxic stress thus triggers severe 
PARylation-dependent NAD+ and ATP depletion ending up in cellular energy crisis44-46. Yet, 
other studies challenge the NAD+ exhaustion model as only reason for cell death. Although 
after middle cerebral artery occlusion (MCAO)-induced ischemia ARTD1 knock-out mice 
have reduced infarct sizes compared to wild-type animals, the energy status of the cells were 
similar47. In addition, another study showed that reduced NAD+ levels do not always correlate 
with reduced ATP levels during ischemia reperfusion injury48. Moreover, PARG-deficient 
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cells induce parthanatos without NAD+ exhaustion49. Thus, PARylation-induced NAD+ 
depletion is not exclusively responsible for cell death50.  
 The initial observation that ARTD1 hyper-activation resulted in cell death by the 
release of the apoptosis-inducing factor (AIF) from the mitochondria51, lead to the definition 
of parthanatos as a new necroptosis module52. Parthanatos, a name derived from par for PAR 
polymer, and Thanatos the personification of death in Greek mythology, is a caspase-
independent mode of cell death that combines apoptotic and necrotic features50,53. The 
function of AIF under physiological and pathophysiological roles has been extensively 
studied54. Whereas the main pool of AIF localizes to the mitochondrial intermembrane space 
and plays essential roles in the mitochondrial respiratory chain and is involved in redox-
metabolism54, a smaller pool of AIF associates to the outer mitochondrial membrane 
(cytosolic side)55. Impaired AIF expression in vivo increases oxidative stress in the brain and 
retina proposing a function as free radical scavenger in mitochondria56-58. Experiments in 
neurons and HeLa cells subjected to genotoxic stress or the ectopic delivery of in vitro 
generated PAR into cells identified the PAR polymer as major contributor of cell death59,60. 
AIF has been identified as a high affinity PAR-binding protein via three critical amino acid 
residues (Arg588, Lys589 and Arg592)61,62. Mutants maintain their NADH oxidase activity, DNA 
binding and chromatin cleaving properties, but fail to leave the mitochondria46. In line with 
the aforementioned mechanistic insights, cell death was abolished by either administrating 
PAR neutralizing antibodies or by overexpressing PARG59,60. The accumulation and 
translocation of complex nuclear PAR molecules into the cytoplasm causes the release of AIF 
from the mitochondria and the induction of chromatin condensation and DNA 
fragmentation63. The exact mode of DNA cleavage is currently under debate, since murine 
AIF does not possess recognizable structural DNA-binding motifs, while human AIF 
does64,65. Additionally, it is not known whether AIF possesses an intrinsic endonuclease 
activity or whether it recruits a proposed parthanatos AIF-associated nuclease (PAAN)53. 
 Characteristically, cells dying from parthanatos, like other necrotic cells lose their 
membrane integrity that releases intracellular material into the extracellular space, of which 
some components function as DAMPs24. The high mobility group box 1 protein (HMGB1) is 
among the most studied DAMPs and recognized by toll-like receptor 4 (TLR4) and receptor 
for advanced glycation endproducts (RAGE). Under physiological conditions HMGB1 
functions as a DNA binding protein that stabilizes nucleosomes and regulates transcription66. 
In contrast, during necrotic cell death, HMGB1 is released in an PARylation dependent 
manner, a process also identified during autophagy67,68. Hence, ARTD1 does not only regulate 
cell fate by depleting cellular energy pools (see above), but also specifically induces immune 
responses via HMGB1. This concept is strengthened by a recent publication, where ARTD1 is 
activated in macrophages by reactive oxygen species (ROS) and/or MAPK-signaling and 
INTRODUCTION 
9 
induces HMGB1 release69. Mechanistically, HMGB1 PARylation seemed to facilitate its 
acetylation, an essential prerequisite for the release69. The latter model could explain how 
immune cells actively secrete HMGB1 after the initiation of the TLR signaling. 
3. ADP-ribosylation during immune responses initiation 
Inflammation is orchestrated by different cell types that integrate diverse stimuli for the 
generation of a specific immune response to kill invading pathogen and/or to clear and 
regenerate damaged tissue1. A typical immune response can be divided in three phases: A 
recognition and initiation phase, a second amplification and modulation phase followed by a 
third effector phase2. Whereas the innate immune system senses and initiates inflammation, 
both innate and adaptive immune systems regulate the second and third phase3. 
 Not only immune cells such as the antigen presenting macrophages or dendritic cells 
but also epithelial, endothelial and fibroblast cells express pathogen recognition receptors 
(PRRs) that initiate innate immune responses4. PRRs recognize a variety, but yet defined set 
of conserved PAMPs, such as bacterial and fungal cell wall components (i.e. 
lipopolysaccharides, LPS) or DAMPs (Figure 3). The recognition of DAMPS and PAMPs, 
often by the same receptors, activates intracellular signaling pathways, which are controlled 
by different ARTD-family members and result in the expression of proinflammatory 
cytokines such as IL-12, IL-23, IL-6 and IL-1β6. The following chapter focuses mainly on 
reports that involved inflammatory stimuli and cells, mostly excluding findings from tumor 
research. For information about tumor cell signaling, readers are advised to consult respective 
reviews12,34,43. 
Figure 3. The immune response. Immune responses (Th1 and Th2) are orchestrated by specialized 
cell types in three distinct phases. Cells of the innate immunity (Sensors) sense PAMPs or DAMPs and 
initiate the first phase by level 1 cytokines. The activation of lymphocytes characterize the second 
phase of an immune response and level 2 cytokines determine the third phase: Effector functions and 
elimination of the pathogen. Figure adapted from Iwasaki et al (2005)70. 
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3.1. ARTD1 co-activates NF-κB dependent gene expression 
While both the recognition of PAMPS (i.e. LPS) or DAMPs (i.e. HMGB1) by TLRs and the 
TLR-induced cytoplasmic signaling events in different cell types do not seem to be regulated 
by ARTs, several reports have described the involvement of ARTD1 during the 
transcriptional activation of proinflammatory genes by PAMPs. However, nothing is known 
so far about ARTD1 function during DAMP-mediated inflammatory signaling. In LPS- but 
also TNF-α stimulated macrophages71-74, microglia75,76, fibroblasts72,75,77,78, endothelial cells76 
and smooth muscle cells71,73,78, ARTD1 was found to promote the NF-κB dependent 
expression of proinflammatory cytokines. The transcription factor NF-κB represents the most 
studied inflammatory transcription factor (TF) so far7. The eukaryotic NF-κB family consists 
of five proteins, p65 (RelA), RelB, c-Rel, p105/p50 (NF-κB) and p100/52 (NF-κB1). 
Dimerization of the different subunits can result in 15 different combinations, the p50/p65 
heterodimer being the most abundant one8. In its inactive form the p50/p65 heterodimer is 
bound by IκB, inhibiting its nuclear translocation79. TLR-mediated signaling (Figure 4) 
induces the canonical NF-κB by activating a signal cascade leading to the phosphorylation of 
IκB, its subsequent ubiquitination and degradation80. In turn, p50/p65 translocate into the 
nucleus.  
 Different mechanistic models have been reported how ARTD1 influences NF-κB-
dependent gene expression. ARTD1 acts as a transcriptional co-factor for NF-κB and 
promotes gene expression by functional cooperation with the transcription machinery in 
response to proinflammatory stimuli81. LPS- and TNF-α-induced NF-κB dependent gene 
expression in macrophages and fibroblasts was enhanced by ARTD1 independently of its 
enzymatic activities, but by complex formation with the mediator complex, p300/CBP and the 
p50 and p65 subunit of NF-κB82,83.  
Mutating the ARTD1 cleavage site Asp214 renders ARTD1 uncleavable and inhibited 
its release from chromatin and chromatin decondensation, thereby restraining the expression 
of cleavage-dependent NF-κB target genes. Interestingly, knock-in mice expressing the non-
cleavable ARTD1 (D214N) mutant were highly resistant to endotoxic shock and to intestinal 
and renal ischemia-reperfusions. This was associated with reduced inflammatory responses in 
the target tissues and cells due to the compromised production of specific inflammatory 
mediators37. Despite normal binding of NF-κB to DNA, NF-κB-mediated transcriptional 
activity was impaired in the presence of caspase-resistant ARTD1. LPS stimulation of 
macrophages activated caspase 7 by caspase 1, induced its translocation to the nucleus, and 
cleaved ARTD1 at the promoters of a subset of NF-κB target genes (e.g CSF2, IL6 or LIF), 
thus negatively affecting their gene expression84. These findings propose an apoptosis-
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11 
independent regulatory role for caspase 7-mediated ARTD1 cleavage in proinflammatory 
gene expression and provide insight into inflammasome signaling. 
In contrast to these reports suggesting that not the enzymatic activity of ARTD1, but 
only the protein itself is required for NF-κB target gene expression, another group reported 
that LPS treatment of macrophages induced ARTD1’s enzymatic activity and nucleosome 
remodeling at promoters of proinflammatory genes, directly destabilizing histone-DNA 
interactions and facilitating NF-κB binding and gene expression85. The discrepancies could be 
explained by methodological differences such as the cell type (RAW.267.4 macrophages and 
primary BMDM or fibroblasts), the source of LPS (S. enterica and E. coli) or the serum 
starvation overnight prior LPS stimulation. 
 Proinflammatory mediators such as Il1b86, Il687, Tnfa75,76 and Cxcl278; and adhesion 
molecules such as Icam1, Vcam or Eselectin87,88 were significantly lower expressed in 
ARTD1 knock-out cells. In LPS stimulated glial cells, ARTD1 also enhances the DNA 
binding of the transcription factors SP-1, YY-1, AP-1 and STAT1 independently of its 
enzymatic activity88. Although the exact mechanisms are unknown, Il6, Il1b and Tnfa 
expression were markedly reduced in ARTD1 knock-out glial cells88.  
 These findings are supported by the fact that ARTD1 knock-out mice are resistant to 
LPS-induced shock89. So far, other ARTD family members have not been implicated in the 
initiation of inflammation. The fact that ARTD1 knock-out mice are resistant to endotoxic 
shock suggests a dominant role of ARTD1 during inflammatory signaling. 
Figure 4. TLR2, TLR3 and TLR4 signaling pathways90. Pattern recognition by TLR receptors 
trigger distinct signaling cascades either via MyD88 and NF-κB or via TRIF and IRF8 to express 
proinflammatory genes. 
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3.2. ADP-ribosylation regulates mRNA stability 
Although transcription is a highly regulated step during the expression of cytokines, cells 
evolved posttranscriptional mechanisms to regulate the translational machinery and the 
conversion of mRNA into protein91,92. This is particularly important for immune effector 
proteins to either re-program gene expression at a global level or modulate the stability and 
translation of specific immune transcripts18. One of the central aspects of the 
posttranscriptional regulation is mRNA stability. Indeed, ARTD1 was identified to promote 
mRNA stability of individual transcripts during LPS-induced proinflammatory signaling in an 
enzymatically dependent manner93. ADP-ribosylation of specific RNA-binding proteins 
modulate RNA processing including splicing, polyadenylation, translation, miRNA 
biogenesis and rRNA processing94. Upon LPS stimulation of macrophages, adenylate-
uridylate-rich element-binding protein embryonic lethal abnormal vision-like 1 
(Elavl1)/human antigen R (HuR) was described to be PARylated95. ARTD1-mediated 
PARylation of HuR enhanced nucleoplasmatic shuttling and mRNA binding, and promoted 
mRNA stablility96. Comparably, pharmacologic inhibition of ARTD1 reduced mRNA 
stability of e.g. Cxcl2 during inflammation93. 
 Additionally, LPS-induced expression of Tf (tissue factor) is an important link 
between inflammation and thrombosis. In LPS-treated macrophages, ARTD8 was identified 
to negatively regulate Tf mRNA stability, by forming a complex with the mRNA destabilizing 
protein tristetraprolin (TTP) and a conserved adenylate-uridylate-rich element in the Tf 
mRNA 3` untranslated region resulting in tissue factor mRNA degradation93. Beside ARTD8, 
no other ARTD family member was described to affect these steps so far. 
4. ADP-ribosylation during immune response modulation 
The cytokines and chemokines that are expressed during the initiation of an immune response 
activate and recruit lymphoid cells, including innate lymphoid cells (ILCs) such as NK-cells 
but also adaptive immune cells like T and B cells. For example, during this second phase of 
inflammation NK cells produce high levels of IFN-γ to amplify the immune response and 
promote Th1 immune responses. Additionally, CD4 T cells differentiate into T helper type 1 
cells expressing additional IFN-γ with a certain delay, repressing Treg and Th17 immune 
responses.  
4.1. ADP-ribosylation controls T cell activation and survival 
Bone marrow-derived lymphoid progenitor cells migrate to the thymus to give rise to T cells, 
which will subsequently seed to peripheral lymphoid tissues97. A critical balance between cell 
division and cell death must be maintained to ensure T cell homeostasis throughout life98. 
With respect to T cell development, Artd2-/- mice were reported to have a to two-fold 
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reduction in the CD4 CD8 double positive (DP) thymocytes associated with decreased DP cell 
survival and increased apoptosis99. Although ARTD1 and ARTD2 do not influence peripheral 
T cell homeostasis individually, their double deficiency leads to severe DNA damage, cell 
death and diminished T cell numbers in peripheral lymphoid tissues100. In addition, T-
dependent antigen-treated (TNP-KLH) Cd4-Cre Artd2flox/flox Artd1-/- mice exhibited defective 
antibody responses determined by decreased IgM and IgG1 serum levels 14 days after 
treatment, suggesting defective T and B cell cooperation100. 
Membrane receptors are crucial initiators of signal transduction in T cells and activate 
T cells to proliferate and differentiate101. Necrotic cells that lost their membrane integrity 
release NAD+ into the extracellular space. In presence of extracellular NAD+, ectopically 
expressed ARTC2.2 mediates on CD4 and CD8 T cells ADP-ribosylation of the purinergic 
P2X7 receptor at Arg125, which induces a Ca2+ influx, macropore formation, 
phosphatidylserine exposure, CD62L shedding, and accelerated cell death (Figure 5)102-104. 
Additionally, necrosis-activated ARTC2 modifies LFA-1, CD8, CD27, CD43, CD44 and 
CD45 on the surface of CD8 cytotoxic T cells, resulting in decreased proliferation and 
decreased cytotoxicity105. Thus, ARTC2.2 acts as a safeguard to prevent undesirable T cell 
activation during necrosis.  
 
Figure 5. Cellular consequences of P2X7 activation on mouse T cells. ARTC2.2-mdiated ADP-
ribosylation of the purinergic P2X7 receptor on mouse T cells leads to its activation and ultimately to 
cell death. Figure taken from Rissiek et al (2015)106. 
4.2. ADP-ribosylation regulates gene expression in activated T cells 
TGF-β and IL-6 promote naïve CD4 T cells differentiation towards proinflammatory Th17 
cells that are characterized by the expression of IL-17 and IL-22107. In contrast, TGF-β and 
IL2 drive naïve CD4 T cells differentiation into CD4+ CD25+ regulatory T cells (Treg) that 
play an important role during immune homeostasis108,109. Balancing the differentiation of 
proinflammatory Th17 as well as regulatory Treg allows establishing a protective and not 
harmful immune response. In CD4 T cells ARTD1 represses the expression of both subunits 
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of the TGF-β receptor: Whereas the expression of TGFbRI is repressed by ADP-ribosylation, 
the expression of TGFbRII is repressed only by the ARTD1 protein110. ARTD1 knock-out 
CD4 T cells expressed increased levels of both TGF-β receptors, which was associated with 
enhanced Smad2/3 activation and up regulation of FoxP3, the master transcription factor of T 
helper cell differentiation110. Studies confirm ARTD1 function during Treg differentiation, 
associated with increased numbers of FoxP3+ Treg cells in lymphoid organs of ARTD1 
knock-out mice compared to wild-type mice111,112. 
 T cell activation is not only driven by cytokines but also by the engagement of the T 
cell receptor (TCR) with the major histocompatibility complex (MHC)-bound antigens on 
cells. TCR activation triggers the activation of receptor-associated tyrosine kinases that lead 
to the activation of phospholipase C-γ (PLC-γ) signaling cascade and intracellular Ca2+ 
release113. T cells express three (NFAT1/NFATc2, NFAT2/NFATc1 and NFAT4/NFATc5) of 
the four Ca2+ regulated nuclear factor of activated T cells (NFAT) transcription factors113. 
Under basal conditions NFAT proteins reside highly phosphorylated in the cytoplasm. The 
calmodulin-dependent phosphatase calcineurin dephosphorylates NFAT proteins, allowing 
nuclear translocation and DNA binding114. During PMA/Ionomycin-induced T cell activation 
(which mimics the TCR activation), ARTD1 was shown to interact with NFATc1 and 
NFATc2 in the nucleus and to modify the proteins115. In particular for NFATc2 the 
PARylation site could be determined at its regulatory region spanning amino acids 1–460. 
Interaction studies suggest that the modification is mediated by direct interactions between 
ARTD1 and NFATc1 and NFATc2 respectively. NFAT PARylation delays its nuclear export 
and enhances NFAT-dependent gene expression. Thus, ARTD1 knock-out T cells exhibit 
markedly reduced Il2 and Il4 expression114. 
 TCR activation can also be accomplished by specific antibodies (i.e. anti-CD3) in 
vitro. Anti-CD3 or anti-CD3/anti-CD28 mediated T cell activation implicated ARTD1 in T 
cell polarization. Microarray-mediated transcriptional profiling revealed increased T helper 
type 1 (Th1) cytokine (Ifng) and chemokine (Cxcl1, Ccl4 and Ccl9) expression and a reduced 
Il4 expression in ARTD1 knock-out pan T cells116.  So far, nothing is known about ADP-
ribosylation and the posttranscriptional control during the amplification and modulation phase 
of an immune response. Furthermore, ADP-ribosylation has not been connected to NK cell 
function that amplifies acute phase immune responses. 
5. ADP-ribosylation during immune response effector phase 
To eliminate pathogens, infected or necrotic cells, the immune system relies on innate and 
adaptive immune cells. Typically, effector functions of the innate immune system, such as 
macrophages and neutrophils are quickly recruited, but do not discriminate well between 
microbial and host targets, so collateral damage to host tissues is unavoidable22. Severe 
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pathogenic infections are usually linked to tissue damage, the release of DAMPs and 
secondary inflammatory reactions117. To do so, macrophages produce high levels of nitric 
oxide (NO) to lyse the pathogen, neutrophils are recruited to the site of infection to produce 
antimicrobial oxygen radicals and epithelial/endothelial cells close their tight junctions to 
prevent the spreading of the pathogen70. 
In contrast, cells of the adaptive immune system, such as cytotoxic CD8 T cells 
specifically recognize only infected cells by T cell receptor – MHCI interactions118. 
Additionally CD4 Treg cells modulate and manage the immune response without direct 
cytotoxicity towards infected cells. Another mechanism to clear evading pathogens very 
specifically are antibody-producing plasma B cells that also establish immunological 
memory. 
5.1. ADP-ribosylation regulates effector cell-specific gene expression 
In macrophages, glial cells and fibroblasts, ARTD1 functions as co-factor of NF-κB (see 
above) to enhance inducible nitric oxide synthase (iNOS) expression72,88. Beside its cytotoxic 
role during pathogen killing, increased NO production leads to increased genotoxic stress for 
host cells. During severe pathogen infections ARTD1 is believed to increase the genotoxic 
stress of cells via iNOS-mediated NO production ultimately driving cells into necrosis117, 
thereby linking bacterial infections and necrosis. Thus ARTD1 drives tissue injury in a 
positive feedback loop and serves as a critical immunecheckpoint for the host to prioritize 
pathogen elimination over cell death119. 
 Historically, each myeloid cell type was assigned to a specific type of infection: 
Macrophages/neutrophils to microbial infections (M1) and eosinophiles/basophiles to 
helminth infections (M2)70. Especially for macrophages the view has drastically changed from 
a simple LPS/IFNγ-induced M1 or IL4-induced M2 polarization model to a more diverse 
concept, where the macrophage origin and the specific activation state determine the effector 
function120. A recent publication identified ARTD8 and ARTD9 as opposing regulators 
during macrophage polarization121. Whereas ARTD8 depletion during M(IFN-γ) polarization 
enhanced STAT1 phosphorylation and gene expression of inflammatory cytokines (i.e. TNF-
α and Il-1β), ARTD9 depletion resulted in decreased STAT1 phosphorylation and decreased 
proinflammatory gene expression121. Mechanistically, the authors provided evidence that 
ARTD8 ADP-ribosylated STAT1 at the C-terminal AA residues Glu657 and Glu705, which was 
abolished in the presence of ARTD9. The expression of ADP-ribosylation deficient mutants 
of STAT1 enhanced its phosphorylation and the expression of Nos2, Il1b and Ccl2121. 
Additionally, during M(IL-4) polarization, ARTD8 depletion reduced STAT6 
phosphorylation and Arg1 expression121. Thus, ARTD8 suppresses M(IFN-γ) polarization and 
enhances M(IL-4) polarization.  
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 During IL-1β and TNF-α mediated signal transduction, ARTD10 was identified to 
play an important role in NF-κB activation122. Both cytokines initiate the tumor-necrosis 
factor receptor-associated factor (TRAF) protein, which function as K63-specific E3 ubiquitin 
ligases synthetizing K63-pUB chains on TRAF itself. ARTD10 binds to K63-pUb, 
MARylates NF-κB essential modulator (NEMO) whereby its polyubiqination and subsequent 
degradation is inhibited. The degradation of NEMO would release IKK-α and IKK-β to 
phosphorylate IκB allowing nuclear translocation of NF-κB. Thus, ARTD10 dampens NF-kB 
gene-expression (i.e. IL-8) in HeLa and U2OS cells.  
 Another important cell type for the elimination of pathogens are neutrophils123. 
Neutrophils are recruited to the site of inflammation by chemotaxis to release high levels of 
genotoxic radicals. ARTC1 expression is markedly increased in chemotaxin stimulated 
neutrophils (i.e. by fMLP, IL-8 or the platelet activating factor)124, which has a profound 
impact during neutrophil effector function125. Activated neutrophils produce antimicrobial and 
cytotoxic HNPs (human neutrophil peptide), which can activate epithelial cells or recruit T 
cells125. Indeed, ARTC1 modifies HNP-1 in vitro, suggesting that modified HNP-1 could 
inhibit its antimicrobial and cytotoxic activity, while retaining its T cell chemoattractant 
abilities in vivo126,127. 
5.2. ADP-ribosylation influences immunoglobulin class switching in B cells 
Antibodies are produced by B cells and are central mediators of immunity, since they 
neutralize pathogens or pathogen-derived products and recruit cellular immune effectors to 
eliminate infections128. Antibodies are classified according to their constant region into IgM, 
IgD, IgG, IgA and IgE. By default, naïve B cell express IgM and IgD surface antibodies, but 
the immunoglobulin class (isotype) can change during the course of an infection depending 
on the nature of the eliciting antigen or its entry route129. 
 Under basal conditions, ARTD1 inhibition or ARTD1 knock-out increased class 
switching frequency to IgA, IgG1 or IgG2 and decreased the switching frequency of IgG2a by 
unknown mechanisms130. The data supports earlier findings reporting that nicotinamide 
treatment increases IgA producing B cells131. Although this study did not analyze whether 
ARTD1’s catalytic activity is required for the observed phenotype, the authors speculated 
about ARTD1’s function as a co-factor during the DNA double-strand forming class 
switching process130. 
 Immunoglobulin class switch is also induced by cytokines. In IL-4 stimulated B cells 
ARTD8 was identified as a transcriptional switch during STAT6-dependend gene 
activation132. Mechanistically, in the absence of the class-switch stimulating cytokine IL-4, 
ARTD8 associates with HDAC2 and HDAC3 to repress Iε (IgE) gene expression. IL-4 
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activates ARTD8 and leads to the dissociation of the HDACs from the promoter, to 
expression of Iε and to IgM to IgE class switching 132. 
6. ADP-ribosylation inhibitors (i.e. PARP inhibitors) 
Historically, ARTD1 and ARTD2 are known for their role during DNA damage response 
(DDR), particularly the base excision repair (BER) pathway and double strand break (DSB) 
repair pathway, although both proteins likely regulate independent, but intrinsically linked 
aspects of DNA base damage response12,26,133. These involvements lead to the development of 
small-molecule ADP-ribosylation inhibitors (i.e. PARP inhibitors; PARPi).  
Figure 6. Synthetic lethal interaction between ARTD1 and BRCA1/2. Single strand breaks (SSB) 
are repaired by the base excision repair (BER) pathway in an ARTD1/PARP1 dependent manner (left 
panel). PARPi treated cells accumulate SSB eventually leading to double strand breaks and replication 
fork collapse. BRCA deficient cells cannot initiate homologous-recombination repair pathways, thus 
leading to cell death (right panel). Figure taken from McLornan et al (2014)134. 
 
The underlying concept was that the inhibition of the DNA-repair machinery could sensitize 
tumor cells to conventional DNA-damage-based therapies such as chemo- or radiotherapy 
(Figure 6)135. 
More than 30 years ago, nicotinamide and nicotinamide derivatives, including 3-
aminobenzamide (3-AB) were identified as the first PARP inhibitors136-138. Advances in drug 
design and screening lead to the discovery of several new generations of PARPi compounds, 
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all of them competing with NAD+139. Today, some of these PARPi are clinically approved as 
anti-cancer agents, including veliparib (Abbvie), rucaparib (Pfizer/Clovis), olaparib 
(KuDOS/AstraZeneca), niraparib (Merck/Tesaro) and talazoparib 
(Lead/Biomarin/Medivation/Pfizer)117,140. Two cancer treatment strategies with PARPi have 
been suggested: Either combinatorial therapies of PARPi and chemo- or radiotherapy141 or 
PARPi monotherapy142. BRCA-deficient breast and ovarian cancers seem particularly 
sensitive to PARPi. The tumor suppressors BRCA1 and BRCA2 are essential proteins for the 
DNA DSB repair machinery to resolve DSBs by homologous recombination (HR)142. Defects 
in HR results in the accumulation of genetic alterations that promote tumorigenesis. In 2005, 
two independent groups discovered a synthetically lethal interaction between ARTD1, 
BRCA1 and BRCA2143,144. Synthetic lethality describes a genetic interaction in which single-
gene defects are compatible with cell viability, but the combination (or synthesis) of gene 
effects results in cell death142. Thus, BRCA mutated cells are up to 1000 times more sensitive 
to PARPi than wild-type cells144. Recently, another PARPi mode of action called “PARP 
trapping” was proposed for a subset of PARPi (especially rucaparib, olaparib, niraparib and 
talazoparib)145,146. Inhibitor-bound ARTD1 is “trapped” to the DNA and interferes with 
ARTD1 function and/or replication resulting in cell death147.  
 Although the potency and specificity of PARPi greatly enhanced during the last 
decades, ART-specific PARPi are still missing148. Interestingly, PARPi have also been 
reported to dampen different inflammation types, strongly corroborating the notion that ADP-
ribosylation also regulates one or several inflammatory processes and that this might also 
contribute to the anti-tumor activity of PARPi81,135,149. At which stage of inflammation and to 
which extent this effect is cell type specific is currently under investigation. 
7. Anti-inflammatory effects of PARPi  
Beneficial effects of PARPi have been implicated in numerous inflammatory disease models 
like neurological diseases, sepsis, chronic inflammatory diseases and reperfusion 
injuries36,117,150,151. 
7.1. Neurological diseases 
Excessive release of the neurotransmitter glutamate results in hyper-activated neurons 
characterized by massive Ca2+ influx. Calcium-mediated activation of various enzymes 
including endonucleases, proteases and neuronal nitric oxide synthase (nNOS) ensuing in 
neuronal excitotoxicity152,153. NO and superoxide form highly reactive peroxynitrile154. 
Endonuclease- and peroxynitrile-induced DNA breaks activate ARTD1, leading to 
parthanatos and inflammation. In fact, ROS, reactive nitrogen species (RNS), DNA alkylating 
agents and glutamate receptor agonists efficiently activate parthanatos in neuronal cells155-157. 
Further in vivo studies suggest important therapeutic opportunities of PARPi for the treatment 
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of neuronal inflammatory diseases such as Parkinson`s disease (PD), stroke and cerebral 
ischemia46. Mouse models identified both ARTD1 hyper-activation and AIF translocation as 
characteristic features of the diseases, which are significantly lowered or absent in ARTD1 
deficient mice or administrating PARPi158-160.  
7.2. Septic shock 
Sepsis is defined as a life-threatening organ dysfunction caused by a deregulated host 
response to infection, eventually leading to septic shock, the more severe form associated 
with increased mortality161. The high bacterial load of typically Gram-negative bacteria 
ultimately results in hypotension and multiple organ failure including liver, kidney and 
heart162. The bacterial cell wall component LPS induces the expression of important 
inflammatory mediators, such as TNF-α, IL-1β, IL-2, IL-6, IL-8, adhesion molecules and 
iNOS which determine the pathologic outcome163. So far, two not mutually exclusive models 
have been proposed to explain the relationship between ARTD1 and LPS-induced septic 
shock139: First, ARTD1 regulates proinflammatory gene expression as a co-factor of NF-κB 
(discussed above in detail)139. Second, excessive production of anti-microbial ROS, RNS or 
radicals by macrophages and neutrophils, induce DNA-damage of host cells resulting in 
necrosis and parthanathos117. In line, pharmacologic inhibition or knock-out of ARTD1 
reduces the inflammatory burden significantly89,164-166. 
7.3. Chronic inflammatory diseases 
PARylation not only influences acute phase, but also various chronic inflammatory diseases 
such as Rheumatoid Arthritis (RA) and diabetes117. RA is an autoimmune disease of the 
peripheral joints. Chronic inflammation leads to the destruction of bones and cartilage, 
thereby impairing joint function167. RA is initiated by an immune response against unknown 
antigens and followed by monocytes/macrophages, B and T cells infiltration into the affected 
joint where they produce proinflammatory mediators. Additionally, the expression of matrix-
metalloproteases cause bone and cartilage degeneration167.  
 PARPi studies discovered reduced incidence and severity of RA in mouse models 
under PARPi treatment, associated with reduced ROS/RNS levels and reduced neutrophil-
infiltration into the joints168,169. Additionally, PARPi decreased the expression of 
proinflammatory cytokines and the Th1-driven immune response170. Pharmacologic inhibition 
or RNAi-mediated knock-down of ARTD1 partially impaired NF-κB and AP-1 binding and 
activation in synovial fibroblasts171. 
 Type I Diabetes is an autoimmune disease against insulin-producing pancreatic β-
cells and is most prevalent in children and young adults. Specific destruction of β-cells results 
in decreased glucose uptake, increased glucagon secretion and hypoglycemia172. So far the 
underlying mechanisms for β-cell destruction are largely not known, but include the 
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recognition of auto-antigens by T and B cells173. Rodent models of type I diabetes that 
resemble the human pathology use specific β-cells toxins (such as streptozotocin) to deplete 
β-cells in vivo174-176. Animal studies identified NO and various other free radicals and oxygen 
species to be the major cause of β-cell death by DNA damage induced hyperactivation of 
ARTD1 and the induction of apoptosis and parthanatos172. In addition, a study of 
streptozotocin-induced diabetes linked ARTD1 activation and ATP exhaustion to the 
inhibition of proinsulin synthesis in β-cells ultimately resulting in cell death177. In all of these 
models the inhibition of ARTD1 had beneficial effect on the severity of the disease172. 
7.4. Myocardial infarction 
Organs essentially need constant blood supply for proper functioning. For example, coronary 
artery diseases can lead to decreased blood supply to the heart tissue and eventually block 
blood flow resulting in ischemic myocardial tissue178. A rapid restoration of blood flow within 
the infarcted area aims at minimizing irreversible myocardial injury. Despite the benefits of 
reperfusion, the therapies come with adverse effects such as microvascular injury and 
extension of myocyte necrosis, which is in part due to oxidative stress178. 
Studies in vitro identified ARTD1 over-activation, NAD+ depletion and the induction 
of parthanatos in myocytes accounting for myocyte cell death during heart failure179. 
Pharmacologic inhibition of ARTD1 or genetic ablation attenuates myocardial necrosis 
during myocardial infarction180. Moreover, PARPi treatment reduced the expression of 
inflammatory cytokines and decreased neutrophil infiltration to the infarct area181. 
7.5. Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a chronic disorder of the gastrointestinal tract that is 
mainly diagnosed as ulcerative colitis or Crohn`s disease182,183. Although the exact cause of 
the disease is unknown, hallmarks of IBD include a diffuse mucosal inflammation with 
increased expression of proinflammatory mediators and a significantly augmented infiltration 
of neutrophils182. Genetic ablation or pharmacologic inhibition of ARTD1 provides resistance 
in various hapten-induced colitis rodent models184-188. In addition, the PARPi 3-
aminobenzamide (3AB) reduced spontaneously developing experimental colitis in Il-10 
knock-out mice via reduction of inflammatory cytokine expression189. Although the 
underlying mechanisms remain largely elusive, a recent study in ARTD1 knock-out mice 
suggests that a ARTD1-dependent transcriptional reprogramming of the colon tissue in 
combination with altered colonic microbiota are responsible for the resistance against dextran 
sulfate sodium (DSS)-induced colitis190. 
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8. The role of erasers during inflammation 
Erasers degrade ADP-ribosylation by cleaving glycosidic bonds to generate mono ADP ribose 
that eventually serves as a substrate for ATP production191. Hence, erasers are the biochemical 
and physiological counterpart of writers (i.e. ARTs) and involved in the ADP-ribosylation 
metabolism192. The eraser family includes ARH1, ARH2, ARH3, MacroD1, MacroD2, TARG 
and the founding member PARG7. So far, only PARG has been implicated in inflammatory 
diseases and will thus be discussed here. 
Human PARG has five isoforms with distinct cellular localizations: A 111 kDa 
(nuclear), a 102 kDa (cytoplasm), a 99 kDa (cytoplasm), a 60 kDa (nuclear and cytoplasm) 
and a 55 kDa (mitochondria) isoform193-197. The murine PARG protein exists in two isoforms 
which differ in their N-terminal region: while wild type PARG (PARG110) is a 110 kDA 
protein composed of an N-terminal regulatory domain and a C-terminal catalytic domain, the 
PARG mutant isoform (PARG60) is a 60 kDa protein that lacks the N-terminal regulatory 
domain193,198,199. Interestingly, full ablation of PARG causes embryonic lethality in mice and 
Drosophila. Mice with a hypomorphic deletion of only the nuclear 110 kDa PARG isoform 
(PARG110-/-), but retaining the 60 kDa isoform are viable and fertile, potentially by 
compensatory mechanisms of the 60 kDa isoform198.  
Strikingly, either inhibition or genetic ablation of ADP-ribosylation writers (i.e. 
ARTD1) and erasers (i.e. PARG), protect against many inflammatory diseases. So far, PARG 
has been implicated in different PAMP and DAMP-associated inflammation models, such as 
peritonitis, LPS-induced septic shock, Dinitrobenzene sulfonic acid (DNBS)-induced colitis 
and oxidative-stress induced neuronal cell death192. However, without providing underlying 
molecular mechanisms. During pathogenic infections PARG has opposing functions: While 
PARG inhibition by GPI 18214 protects mice during zymozan (glucan of cell surface of 
yeast)-induced peritonitis, by decreased neutrophil infiltration into the lungs and decreased 
plasma TNF-α and IL-1β levels200, PARG110-/- are hypersensitive to LPS-induced septic 
shock198.  
PARG has also been suggested to promote ischemia-reperfusion-induced tissue 
injuries. For example, PARG inhibition or genetic ablation of PARG in mice and rats 
decreased neutrophil infiltration, endothelial expression of ICAM-1 and P-Selectin and TNF-
α plasma levels during gastrointestinal ischemia201. Moreover, PARG inhibition decreased the 
infarct size in a rat-model of cerebral ischemia reperfusion202. In a model of renal ischemia 
reperfusion, PARG110-/- mice exhibited significantly reduced tissue injury and dysfuntion203. 
Analogously to ARTD1, PARG does also promote IBD. PARG110-/- mice were resistant and 
PARG inhibitor treated mice were significantly protected in a model of DNBS-induced colon 
injury204. Mutant mice exhibited significantly lower colon TNF-α and IL-1β levels. 
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Overall the currently available data suggests important functions of PARG during 
different inflammatory conditions that are worthwhile pursuing in the future. Especially 
PARGi could open new therapeutic opportunities for treating inflammatory diseases. 
However, functional analyses to understand the molecular mechanisms of the 
abovementioned phenotypes are critically needed. Moreover, the role of other erasers during 
inflammation might be attractive targets for further investigations. 
9. ADP-riboslyation as anti-viral defense mechanism 
Viruses are non-living biological agents which only replicate in infected host cells, hence 
“hijack” the cellular machinery to generate new viral particles. Successful virus replication in 
infected cells is strongly determined by the balance between two competing processes: (i) the 
ability of cells to sense virus-specific PAMPs and (ii) the ability of viral proteins to interfere 
with the cellular response to viral infection205. In fact, cells rely on ARTD1 family member 
dependent defense mechanisms during different phases of viral replications. 
 Interferon stimulated cells are primed for antiviral responses and express various 
antiviral genes. Recently, Zhang et al identified the ARTD9-deltex E3 ubiquitin ligase 3L 
(DTX3L) interaction as potent antiviral mediators206. During interferon signaling, ARTD9-
DTX3L and STAT1 interaction activates the E3 ubiquitin ligase activity towards histone H2B 
at distinct chromatin loci to facilitate host proinflammatory gene expression. In addition, 
ARTD9-DTX3L E3 ubiquitin ligase activity also targeted the viral 3C protease degradation 
by the immunoproteasome206. Thus, ARTD9-DTX3L targets host and viral protein to promote 
viral clearance.  
 Host antiviral protein expression during infection is crucial for viral elimination. In 
plants and intervetebrates, the expression of these transcripts is in part regulated post 
transcriptionally by RNAi207. In eukaryotic virus infected cells, ARTD13 reduced RNAi 
activity and promoted interferon-stimulated gene (ISGs) expression. Mechanistically, the 
authors observed a correlation between the poly-ADP-ribosylation of the RNA-induced 
silencing complex (RISC) and ARTD13207. Since ARTD13 is enzymatically inactive, we 
propose that another ARTD family member PARylates RISC in an ARTD13 dependent 
manner. 
 After successful entry into a host cells, viral mRNA needs to be expressed by the host 
transcription machinery. In an elegant search for novel host antiviral factors Gao et al. 
identified a Zinc-finger Antiviral Protein, today known as the catalytically inactive ARTD13 
being a viral RNA binding protein208. Interaction studies identified two RNA helicases (p72 
and DHX30) and exosome components to associate with ARTD13 suggesting that ARTD13 
regulates viral RNA unwinding and exosome degradation 209. So far, ARTD13 inhibits 
various retroviruses including human immunodeficiency virus 1 (HIV-1), or other RNA 
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viruses such as Alphaviruses and Filoviruses209. Recently, ARTD14/PARP7 has been 
identified to sense viral RNA as well and initiate viral RNA degradation in an exosome-
dependent manner210. Thereby ARTD14 inhibits Sindbis Virus replication in host cells. 
 Viral replication oftentimes occurs in the nucleus of the infected cell. Under basal 
conditions, tankyrase 1 and tankyrase 2 (ARTD5 and ARTD6) regulate telomere 
maintenance, WNT-signaling and mitosis211. A recent study identified that during herpes 
simplex virus (HSV) infection, particularly tankyrase 1 is phosphorylated and localized to the 
nuclear viral replication compartment212. HSV did not replicate in tankyrase 1 and 2 depleted 
cells or pharmacologically inhibited (XAV939) cells, suggesting that tankyrase activity 
promote HSV replication. 
 Host ribosomes translate viral transcripts and mediate viral amplification. A recent 
study identified ARTD12/PARP12 to interfere with viral translation205. Mechanistically, the 
data suggests that the longer isoform of the two ARTD12 isoforms, ARTD12L as well as its 
catalytic activity are required for complex formation with ribosomal proteins at polysomes to 
efficiently inhibit venezuelan equine encephalitis virus (VEEV) translation205 
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AIM OF THE THESIS 
ADP-ribosylation plays important roles during various PAMP and DAMP-mediated 
inflammatory conditions. Several in vitro studies identified ARTD1 as promoter-specific 
transcriptional co-activator for NF-κB and critical regulator of proinflammatory gene 
expression in macrophages. Since inflammatory processes involve very complex multicellular 
networks, the lack of cell type specific ARTD1 knock-out mice significantly limit functional 
investigations of ARTD1 in-vivo. In addition, PARPi reduced the inflammatory burden of the 
host, but which cell types are particularly PARPi sensitive and which ARTD family members 
contribute to PARPi activities during inflammation are currently not clear. 
 
The thesis addressed the following specific aims: 
 
(i) To develop a macrophage-specific ARTD1 knock-out mouse and to investigate the 
contribution of ARTD1 in macrophages in vivo using three different models inducing a Th1 
response. 
 
(ii) To investigate in which cell type ADP-ribosylation inhibitors (i.e. Talazoparib or 
Olaparib) affect LPS-induced proinflammatory signaling. 
 
(iii) To identify additional ARTD family members involved in the LPS-induced inflammatory 
signaling response in fibroblasts. 
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ABSTRACT/Summary 
 
Toll-like receptors (TLR) transcriptional activation of proinflammatory genes in 
different cell types has been described to involve ARTD1/PARP1 in vitro. Also Artd1 
knockout mice were protected against PAMPs induced inflammation model. However, it 
is not clear to which extent ARTD1 contributes in vivo to the TH1 polarization in a 
specific cell type. We therefore generated a conditional macrophage-specific Artd1 
knockout strain (i.e. Artd1∆Myel) which was investigated in three different immunological 
models: i) acute systemic LPS-induced inflammation, ii) local gastric Helicobacter pylori 
infection and iii) subcutaneous MC-38 tumor model. We observed that ARTD1 
deficiency in bone marrow-derived macrophages regulated a specific set of genes in an 
enzymatically independent manner and reduced the LPS induced IL-12/IFN-γ  signaling 
in an acute sepsis model in vivo. The loss of ARTD1 in macrophages reduced the TH1 
response to H. pylori and led to H. pylori hyper-colonization of the gastric mucosa. 
Similarly, Artd1∆Myel mice failed to control tumor growth in a subcutaneous MC-38 
xenograft model due to reduced TH1 and CD8 responses. Together, these data provide 
strong evidence that ARTD1 controls type I immunity by regulating IL-12 and IL-18 
expression in macrophages in a manner that is independent of its enzymatic activity.  
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INTRODUCTION 
Inflammation is orchestrated by different cell types that integrate diverse stimuli for the 
generation of a specific immune response to kill invading pathogen and/or to clear and 
regenerate damaged tissue1. Beside immune cells such as the antigen presenting macrophages 
or dendritic cells also epithelial, endothelial and fibroblast cells express pathogen recognition 
receptors (PRRs) that initiate an innate immune response2. PRRs recognize a variety, but yet 
defined set of conserved pathogen associated molecular patterns (PAMPs), such as bacterial 
and fungal cell wall components (i.e. lipopolysaccharides, LPS) or danger associated 
molecular patterns (DAMPs)3. The recognition of DAMPS and PAMPs, often by the same 
receptors, activates intracellular signaling pathways, which are controlled by different 
proteins and result in the expression of pro-inflammatory cytokines such as IL-12, IL-23, IL-6 
and IL-1β 4. IL-12 produced by antigen presenting cells (APCs) in response to certain 
pathogenic infections activates NK cells and promotes TH1 differentiation and interferon  γ 
(IFN-γ) production5. 
 Septic shock is the most common cause of death in intensive care units and it is 
usually the result of a systemic Gram-negative bacterial infection resulting in hypotension and 
failure of several organ systems, in particular the liver, kidney and heart6. The bacterial 
membrane component lipopolysaccharide (LPS), when injected into animals, causes a shock-
like state that can even lead to death. The mechanism by which LPS induces endotoxic shock 
is related to its ability to activate the NF-κB/Rel family of transcription factors, enabling the 
expression of several critical genes involved in the pathogenesis of septic shock mediated by 
an excessive TH1/TH17-predominant responses7. LPS binding to TLR4 induces the activation 
of several primary response genes such as Ifnb1 and Ccl58. Comparably, Helicobacter pylori 
(H. pylori) causes a persistent mucosa-associated but non-invasive infection that is 
characterized by either regulatory T cell (Treg)- or TH1/TH17-predominant responses9. In 
children and neonatally infected mice, the H. pylori/host interaction is generally 
asymptomatic and characterized by a lack of effector T cell responses, predominance of 
Tregs, and high level colonization10,11. Mice infected in adulthood exhibit a striking T cell 
infiltrate that is dominated by effector T cells and limits the bacterial burden without clearing 
H. pylori completely10,11. Rather, the large quantities of IFN-γ produced by H. pylori-specific 
TH1 cells are believed to be the direct cause of the pre-malignant lesions, i.e. epithelial 
hyperplasia and intestinal metaplasia that precede the development of gastric cancer10.  
 Myeloid cells populate the tumor microenvironment12. These myeloid cells are highly 
heterogeneous with cells of both the monocytic and granulocytic lineages, and have 
considerable phenotypic plasticity with both positive and negative effects on tumor growth 
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and metastasis13,14. The balance between anti-tumor and pro-tumor functions can depend on 
the polarization state, the interaction with the tumor microenvironment and/or the tumor 
type12,15,16. Grafting MC38 cells (derived from a mouse colon adenocarcinoma), to a 
genetically identical inbred, immune competent mouse (‘syngraft’ or ‘isograft’) is a way of 
overcoming the species mismatch between tumor and stroma, which likely affects cell 
communication and the use of immune-deficient hosts17. We recently reported that MC-38 
mouse colon cancer cells contain functional hypoxic (HIF-1α) and inflammatory (p65/RelA) 
signaling pathways18. In contrast to cells of the myeloid lineage, HIF-1α levels remained 
unaffected in MC-38 cells treated with LPS, and hypoxia failed to induce NF-κB. The 
correspondent regulation of canonical HIF and NF-κB target genes confirmed these results.  
 Furthermore, we and others have reported that ARTD1 (also known as PARP1) 
promotes NF-κB dependent expression of pro-inflammatory cytokines such as IL-1β, IL-6, 
TNF-α and CXCL-2; and adhesion molecules such as ICAM, VCAM or E-Selectin in LPS- 
but also TNF-α stimulated macrophages and fibroblasts19-21. ARTD1 belongs to the family of 
intracelluar diphtheria toxin-like ADP-ribosyltransferases that covalently attach ADP-ribose 
(ADPr) to amino acid residues of target proteins using nicotinamide adenine dinucleotide 
(NAD+) as substrate. This process is called protein ADP-ribosylation and represents an 
ancient posttranslational modification (PTM) found in a wide range of biological species22-24. 
Protein ADP-ribosylation can either affect the enzymatic activity of the modified protein or 
their interaction with nucleic acids and with other proteins25. The above findings regarding the 
transcriptional regulation of ARTD1 in different cells types is further supported by the fact 
that ARTD1 knock-out mice are resistant to a high dose LPS-induced endotoxin shock 
model26, suggesting a dominant role of ARTD1 during inflammatory signaling. Historically, 
ARTD1 is known for its role during DNA damage response (DDR), particularly the base 
excision repair (BER) pathway and double strand break (DSB) repair pathway27. These 
involvements let to the development of small-molecule ADP-ribosylation inhibitors (i.e. 
PARP inhibitors; PARPi). The underlying concept was that the inhibition of the DNA-repair 
machinery could sensitize tumor cells to conventional DNA-damage-based therapies such as 
chemo- or radiotherapy28. Beside the treatment of cancer patients with PARPi, these 
compounds have also been reported to dampen different inflammation types, confirming that 
ADP-ribosylation also regulates one or several inflammatory processes and that this might 
also contribute to the anti-tumor activity of PARPi28,29. Beneficial effects of PARPi have also 
been implicated in numerous inflammatory disease models30-32. For example, we showed that 
PJ34 could prevent and also cure Helicobacter-associated, T cell–driven immunopathology 
that precedes gastric cancer development. PJ34 exerts its anti-inflammatory effects in a 
Helicobacter model by impairing T cell priming and TH1 polarization in the gut-draining 
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mesenteric lymph nodes33. Our data indicate that PJ34 directly suppresses T cell effector 
functions by blocking the IFN-γ production of mesenteric lymph node T cells ex vivo. 
However, it is not clear whether ARTD1 or another ARTD family member contributes to 
these observations and to which extent ARTD1 regulated a specific cell type that contributes 
to the TH1 polarization. The presence of ARTD1 in the nucleus of LPS-stimulated 
macrophages hinted at its possible role in mediating some nuclear effects elicited by LPS, a 
possibility also suggested by previous reports describing a transcriptional coregulator activity 
of ARTD134-36.  
 To address the role of ARTD1 in macrophages during different inflammatory 
responses, we generated a mouse strain with a Cre-mediated deletion of ARTD1 specifically 
in macrophages. We observed that ARTD1 deficiency in BDMB of regulates a specific set of 
genes in an enzymatically independent manner and reduces the LPS induced IL-12/IFN-γ 
signaling in an acute sepsis model in vivo. Moreover, H. pylori infection in ARTD1∆Myel mice 
induced a reduced IFN-γ expression in gastric CD4 T cells and ARTD1∆Myel mice displayed a 
significantly increased MC-38 tumor growth due to a reduced activation of CD4 and CD8 T 
cells. Together, we provide strong evidence that ARTD1 controls in macrophages the IL-
12/18-IFN-γ axis in an enzymatically independent manner.  
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RESULTS 
 
ARTD1 regulates IL-12/IL-18 gene expression in BMDM in an enzymatic independent 
manner  
 ARTD1 plays important roles in a wide variety of functionally interconnected cell 
types that control inflammation outcomes, including macrophages, dendritic cells, T or B 
cells37, making it difficult to separate the effects of ARTD1 in one cell type from effects in 
other cell type. Thus, studies with whole-body Artd1-null mice in which ARTD1 is absent 
throughout development have often yielded conflicting results38. To avoid these 
complications while examining the specific role of ARTD1 in inflammation, we developed a 
mouse line with a conditional (“floxed”) exon 4 of Artd1 (Artd1flox/flox) (Fig. 1A and S1A, 
S1B). In order to establish that the floxed allele can be inactivated, we first crossed the 
Artd1flox/flox mice with transgenic mice containing a CMV-cre cassette to generate a full body 
ARTD1 knockout (Artd1flox/flox;CMV-cre), hereafter called Artd1del/del (Fig. 1A). The whole 
body ARTD1 deficient mouse developed normally and was fertile comparably to the 
corresponding ARTD1 proficient mouse and the classical Artd1-/- mouse39. Although western 
blotting showed complete loss of ARTD1 in the organs tested (Fig S1C), ARTD1 loss did not 
affect organ weight or organ structure (Figure S1D, data not shown).  
Since we aimed for an investigation on the role of ARTD1 in macrophages 
specifically, we generated bone marrow derived macrophages (BMDM) from Artd1del/del mice 
and confirmed the genetic deletion of the Artd1 gene by qPCR (Fig. S1E). 
 To assess the functional role of ARTD1 in macrophages, BMDM from Artd1del/del 
mice and Artd1flox/flox controls at day 6 of differentiation were treated with LPS/IFN-γ for 4 
hrs, RNA was extracted and the RNA was subsequently analyzed by deep sequencing. We 
compared untreated and LPS/IFN-γ-treated BMDM to directly identify target genes regulated 
downstream of TLR4/IFN-γ-receptor. The overall gene expression patterns in untreated and 
LPS/IFN-γ treated Artd1flox/flox BMDM were quite distinct (Fig. 1B). Stimulation caused a 
robust induction of pro-inflammatory response genes (approx. 2500, Fig 1B), including NF-
κB-dependent genes (e.g. Ifnb1, Ccl5 and Cxcl10), while the expression of many basal 
expressed genes was reduced (approx. 3000; Fig. S1F). When focusing only on the activated 
inflammatory response genes, deletion of ARTD1 reduced the induced expression levels of 
some genes suggesting that ARTD1 would act, as already reported by our group and others, 
as transcriptional co-activator for these genes (Fig 1C, lower panel). The other half of genes 
was upon deletion of ARTD1 further enhanced providing evidence that the lack of ARTD1 
would also negatively affect gene expression (Fig. 1 C, upper panel). Independent qPCR 
RESULTS – Kunze et al 
32 
analysis of a defined set of genes belonging to both clusters confirmed the quantitative RNA-
seq analysis (Fig. 1D). These data suggested that ARTD1 indeed regulated LPS/IFN-γ-
induced gene expression in macrophages in different ways, although the expression of pro-
inflammatory gene expression is rather positively regulated.  
 To gain insight into potential pathways driving LPS/IFN-γ-mediated transcriptional 
regulation and their downstream effects, gene ontology (GO) analyses were performed. 
Analyzing all LPS/IFN-γ-induced genes (Fig. 1B) revealed macrophage characteristic pro-
inflammatory pathways significantly enriched including T cell activation, IFN-γ-production 
and NK cell activation (Fig 1E, left). Next, to investigate the degree of ARTD1 co-activating 
and co-repressing gene expression during LPS/IFN-γ signaling, the previously identified GO 
terms were matched to co-activated genes of ARTD1 (lower expression in ARTD1 
deficiency, identified in Fig. 1C lower panel) and co-repressed by ARTD1 (higher expression 
in ARTD1 deficiency, identified in Fig 1 C upper panel). For all analyzed pathways ARTD1 
co-represses significantly more genes than it activates. The data thus suggests that, globally, 
ARTD1 acts predominantly as a co-activator of pro-inflammatory gene expression rather than 
as a repressor. 
 To investigate whether the observed transcriptional regulation of LPS/IFN-γ induced 
target genes by ARTD1 is dependent on its enzymatic activity, the stimulation experiment 
was repeated in presence of two ADP-ribosylation inhibitors (i.e. PARPi) (Fig. S1G, S1H). 
Although treatment of WT BMDM with PARPi affected the expression of a few genes under 
the tested conditions, the pro-inflammatory genes observed above, where not affected, 
suggesting that the enzymatic activity of ARTD1 in macrophages is not contributing under 
the tested conditions to the innate immune response (Fig. S1G, S1H). 
 To confirm that the observed transcriptional changes are indeed also relevant at the 
protein level, the expression levels of a distinct set of cytokines was confirmed by ELISA 
after treatment of BMDM from Artd1flox/flox  and Artd1del/del mice with LPS/IFN-γ for 18 hrs. 
The quantified levels of IL-12p70, IL-18, IL-6 and TNF-α were all significantly reduced in 
BMDM from ARTD1 deficient mice compared to WT mice (Fig. 1F) strongly confirming 
that ARTD1-mediated transcriptional control affects the TH1-mediating polarization of the 
innate immune response in macrophages in vitro. 
 
Myeloid cell-specific deletion of ARTD1 reduces the LPS induced IL-12/IFN-γ signaling 
in an acute sepsis model in vivo 
Given the above reported results on the impact of ARTD1-deficiency in macrophages 
on their transcriptional reprogramming with respect to their TH1 polarizing potential, we 
investigated in more detail the role of ARTD1 in macrophages in three different animal 
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models that are mediated and regulated by a strong TH1 response.  
Treating mice with a lethal dose of lipopolysaccharide (LPS, 40mg/kg) resulted in the 
rapid activation of NF-κB in macrophages from wildtype but not from ARTD1-deficient 
mice26. ARTD1-deficient mice proved to be extremely resistant to LPS-induced endotoxic 
shock. Although a deficient activation was found in isolated macrophages from ARTD1-
deficient mice injected with LPS, the contribution of ARTD1 specifically in macrophages in 
vivo was not tested due to the lack of conditional knockout mice. To explore the specific role 
of ARTD1 in macrophages in vivo, we first crossed the Artd1flox/flox mice with transgenic mice 
containing a LyzM-cre cassette to generate a conditional ARTD1 knockout in macrophages 
(Artd1flox/flox;LyzM-cre), hereafter called Artd1∆Myel. Mice lacking ARTD1 only in 
macrophages developed normally and were fertile comparably to the corresponding ARTD1 
proficient mouse (data not shown). The macrophage specific targeting was confirmed by 
western blotting for ARTD1 in ex vivo BMDMs and in vivo peritoneal macrophages (Fig. 
S2A). 
 To study the initiation of the innate immune response under non-lethal LPS 
conditions, we performed low dose LPS treatments in Artd1∆Myel mice and controls. 
Artd1flox/flox and Artd1∆Myel mice of 6–12 weeks of age were intraperitoneally (i.p.) injected 
with 4 mg/kg body weight of LPS. Both Artd1flox/flox and Artd1∆Myel mice equally showed a 
series of responses such as fever and lethargy, but none of the animals died during the 4 h 
time course of the experiments (data not shown). Furthermore, the activation of the 
macrophages in vivo following the low LPS i.p. injection was determined using serum 
samples obtained from control or LPS-treated mice. Four hours LPS treatment very strongly 
induced the serum level of IFN-γ, IL-12p70, IL-18, TNF-α and IL-6 (Fig. 2B). The serum 
levels of IFN-γ were significantly reduced in Artd1∆Myel mice, while the other tested cytokines 
were reduced although under the tested conditions not to a significant extent (Fig. 2B). 
Analyses for anti-inflammatory cytokines revealed that except for IL-4, the serum levels of 
IL-10 and IL-13 were unchanged (Fig. S2B), suggesting that the observed differences in 
proinflammatory cytokine levels were not due to an enhanced anti-inflammatory response 
under the tested conditions. Together these data confirm the initiation of an innate immune 
response with the applied low LPS dose and support the in vitro data that ARTD1 deficient 
macrophages fail to express IFN-γ-inducing Il-12 and IL-18.  
 Since the expression of IFN-γ is strongly induced by IL-12/1840, we analyzed the 
transcriptional expression levels of the same cytokines in isolated spleen tissue from LPS 
treated Artd1flox/flox and Artd1∆Myel mice. LPS induced a strong expression of Ifng, Il12b, Il18, 
Tnfa and Il6 mRNA which was significantly reduced in spleen tissue from Artd1∆Myel mice 
(Fig. 2C) indicating that this inflammatory program is strongly regulated by macrophage-
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resident ARTD1.  
 To assess whether the macrophage-specific ARTD1-deletion affects the cellular 
composition of the spleen that could be responsible for altered cytokine production, 
splenocytes from Artd1flox/flox and Artd1∆Myel mice were immunophentoyped by flow cytometry 
using cell type specific markers. These experiments revealed that only the B and CD4 T cell 
counts were significantly increased in untreated Artd1∆Myel compared to the Artd1flox/flox control 
mice, while all the other tested cell types including CD8 T, NK, granulocytes, and most 
importantly macrophages, monocytes or neutrophils were not altered (Fig. S2C), indicating 
that the lack of ARTD1 in macrophages did not affect the macrophage development or 
colonialization of the spleen in vivo. 
 During acute inflammation and the innate immune response IFN-γ is mainly 
expressed from NK and to a lower extent by T cells41. To identify the cell type responsible for 
the observed IFN-γ levels in the spleen (Fig. 2C) and the serum (Fig. 2B), we performed an 
intracellular staining for IFN-γ in NK, CD4 and CD8 T cells isolated from the spleen of LPS 
treated Artd11flox/flox and Artd1∆Myel mice (Fig. 2D). In all three cell types, LPS treatment lead 
to a detectable IFN-γ level, although the number of NK cell expressing IFN-γ was 
considerably higher compared to CD4 and CD8 T, suggesting that NK cells from spleen are 
the main cell type responsible for the observed differences in IFN-γ expression (Fig. 2D). 
Moreover, in Artd1∆Myel mice only the numbers of IFN-γ positive NK cells were lowered but 
not the ones of IFN-γ expressing CD4 and CD8 T cells, suggesting that ARTD1-deficiency in 
macrophages mainly affects the IFN-γ levels in NK cells. To exclude that NK cells from 
Artd1flox/flox and Artd1∆Myel mice were differently responsible to IFN-γ-inducing IL-12/18 
signaling, isolated NK cells from both cell types were isolate and stimulated for 18 hrs with 
IL-12p70 (10 ng/ml) and subsequently the IFN-γ expression was measured by ELISA. 
Stimulation of the NK cells from both mouse strains induced the IFN-γ expression in an IL-
12p70 dependent manner and most importantly to the same extent (Fig. 2E), providing strong 
evidence, that the reduced IFN-γ levels in Artd1∆Myel mice are indeed due to the reduced 
production of IL-12/18 cytokines in macrophages and that ARTD1 is an important 
transcriptional activator for these genes. 
 
ARTD1 expression by macrophages is required for TH1 responses and bacterial immune 
control  
Immunocompetent adult C57BL6 mice infected with the human gastric pathogen H. pylori 
exhibit a striking T cell infiltration that is dominated by TH1- and TH17-polarized CD4 T-cells 
and limits the bacterial burden9. The large quantities of IFN-γ and IL-17 produced by H. 
pylori-specific TH1 and TH17 cells are believed to be the direct cause of the pre-malignant 
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lesions, i.e. epithelial hyperplasia and intestinal metaplasia that precede the development of 
gastric cancer42. To investigate the role of ARTD1 in macrophages for the development of H. 
pylori-specific TH1 and TH17 responses we infected Artd1flox/flox and Artd1∆Myel mice with 108 
CFU of the human patient isolate H. pylori PMSSI (Fig. 3A). After 30 days, the mice were 
sacrificed and colony forming unit (CFU) assays of homogenized stomach tissue displayed 
successful gastric H. pylori colonization (Fig. 3A). In addition, H. pylori infected Artd1∆Myel 
stomach homogenates exhibited significantly increased CFU when compared to Artd1flox/flox 
counterparts (Fig. 3A). To test the ability of ARTD1 deficient myeloid cells to initiate a TH1 
and TH17 response we quantified CD4 T cells in the stomach of Artd1flox/flox and Artd11∆Myel 
mice either given PBS or H. pylori. Although a significant H. pylori dependent increase of 
gastric CD4 T cell infiltration was observed 4 weeks post infection, the levels of CD4 T cells 
were similar between Artd1flox/flox and Artd1∆Myel mice (Fig. 3B). To assess the activation status 
of the infiltrated CD4 T cells we quantified IFN-γ and IL-17 expression by intracellular flow 
cytometrical cytokine staining (Fig. 3C). H. pylori infection induced a mild IFN-γ expression 
in gastric CD4 T cells (Fig. 3C), which was slightly decreased in Artd1∆Myel mice compared to 
Artd1flox/flox mice. Additionally, IL-17 was H. pylori dependently induced however not 
differently in Artd1flox/flox and Artd1∆Myel mice. The data suggests that ARTD1-deficient gastric 
macrophages recruit equal numbers of CD4 T cells, but fail to activate them in an IFN-γ-TH1-
dependent manner. 
 
Artd1∆Myel mice displayed a significantly increased MC-38 tumor growth due to a 
reduced activation of CD4 and CD8 T cells 
Understanding the impact of myeloid cells on cancer development could be essential in 
distinguishing and possibly manipulating positive and negative myeloid effectors. Myeloid 
cells recognize tumors and are important initiators of TH1-mediated tumor elimination but 
some subpopulations of myeloid cells have also be described to promote tumor growth 43. To 
investigate the role of myeloid cell-specific ARTD1 to the contribution to tumor growth we 
subcutaneously injected 0.5x106 colon adenocarcinoma MC-38 cells into the flanks of 
Artd1flox/flox and Artd1∆Myel mice. Caliper measurements of the tumor volume demonstrated 
efficient engraftment of MC-38 cells in both mouse strains. From day 6 on, Artd1∆Myel mice 
displayed a significantly increased tumor growth compared to Artd1flox/flox, which lasted until 
the end of the study at day 14 (Fig. 4A).  
 To assess tumor infiltration in Artd1flox/flox and Artd1∆Myel mice we quantified 
macrophages by flow cytometry after 14 days. Increased tumor volume in Atd1∆Myel mice was 
associated with decreased tumor macrophage infiltration (Fig. 4B) and reduced macrophage 
activation in MC-38 tumors (i.e. TNF-α expression) (Fig. 4B). Myeloid cells recruit and 
activate CD4 and CD8 T cells to the tumor site where they differentiate into T helper or 
RESULTS – Kunze et al 
36 
cytotoxic T cells, respectively. Whereas the overall CD4 and CD8 T cell infiltration of 
Artd1flox/flox and Artd1∆Myel mice was similar (Fig 4C) we observed a reduction in their IFN-γ 
and TNF-α expression (Figure 4D). The combined data suggest that ARTD1-deficient 
macrophages infiltrate MC-38 tumors less efficiently and fail to produce TNF-a. Although 
overall CD4 and CD8 T cell recruitment to the tumor microenvironment is similar in 
Artd1flox/flox and Artd1∆Myel mice, their activation and IFN-γ and TNF-α expression is 
significantly reduced thus allowing aberrant tumor growth.Together, the above described 
three models all provide strong insights into the function of ARTD1 in macrophages. In all 
three models, lack of ARTD1 reduced the TH1/TH17 response due to the strongly reduced 
expression of IL-12/18 and subsequently the expression of IFN-γ either in NK cells (acute 
systemic LPS model) or in CD4/8 T cells in the local H. pylori and MC-38 tumor model. 
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DISCUSSION 
In this study, we investigated the role of ARTD1 in macrophages in three different 
immunological models: i) an acute systemic LPS-induced inflammation, ii) a local gastric H. 
pylori infection or iii) a subcutaneous MC-38 tumor model in vivo. We observed that in 
BMDM of ARTD1-deficient mice a specific set of pro-inflammatory genes is regulated in an 
enzymatically independent manner which leads to reduced LPS-induced IL-12/IFN-γ serum 
levels and to altered inflammatory signaling in an acute sepsis model in vivo. Moreover, H. 
pylori infection in Artd1∆Myel mice induced only a reduced IFN-γ expression in gastric CD4 T 
cells, and Artd1∆Myel mice displayed a significantly increased MC-38 tumor growth due to a 
reduced activation of CD4 and CD8 T cells. Together, these data provide strong evidence that 
ARTD1 controls in macrophages the IL-12/18-IFN-γ axis in an enzymatically independent 
manner.  
 To investigate the relevance of ARTD1 in macrophages, we generated conditional 
knockout animals with an ARTD1-deficiency in macrophages. Analyses of the cell type 
composition in the spleen of these animals revealed that only the B and CD4 T cell counts 
were significantly increased in untreated Artd∆Myel compared to the Artd1flox/flox control mice, 
while all the other tested cell types including macrophages were not altered. It is currently not 
clear why B and CD4 T cells counts were increased, but given that the number of 
macrophages was not altered, and an increase of particularly CD4 T cells might have rather 
lead to increased IFN-γ levels upon LPS-stimulation, the observed changes in cell numbers 
rather unlikely contributed to the changes in cytokine expression.  
 Different mechanistic models have been reported on how ARTD1 influences NF-κB-
dependent gene expression. ARTD1 acts as a transcriptional co-factor for NF-κB and 
promotes gene expression by functional cooperation with the transcription machinery in 
response to pro-inflammatory stimuli44. LPS- and TNF-α-induced NF-κB dependent gene 
expression in macrophages and fibroblasts was enhanced by ARTD1 independently of its 
enzymatic activities, by initiating a mediator complex with p300 and NF-κB. Also in these 
presented studies, treatment of BMDM with ADP-ribosylation inhibitors (e.g. Olaparib or 
PJ34) did not affect the expression of LPS/IFN-γ induced gene expression, although some 
non-inflammation related genes were susceptible to the inhibitors. In contrast to these reports, 
another report suggested that LPS treatment of macrophages induced ARTD1’s enzymatic 
activity and nucleosome remodeling at promoters of pro-inflammatory genes, which directly 
destabilized histone-DNA interactions and facilitated NF-κB binding and gene expression45. 
The discrepancies could be explained by methodological differences such as the cell type 
RESULTS – Kunze et al 
38 
(RAW.267.4 macrophages and primary BMDM or fibroblasts), the source of LPS (S. enterica 
and E.coli) or the serum starvation overnight prior LPS stimulation. 
 The LPS-induced expression of IL-12/18 in primary macrophages seemed to be 
dependent on ARTD1 in vitro but also in vivo. Whether these two genes are regulated in a 
similar manner and as indicated above remains to be investigated. The Il12b gene is a well-
studied example of a gene that requires chromatin remodeling during inflammation-induced 
gene expression. Studies of the Il12b promoter identified binding sites for various 
transcription factors including NF-κB, C/EBP, AP-1 and NFAT46-48. However their binding 
sites, -30 to -175 bp upstream the transcription start site, are blocked by nucleosomes and 
require nucleosome remodeling prior transcription49. Indeed the SWI-SNF complex, which is 
responsible for nucleosome positioning50 is recruited to target genes in LPS-stimulated 
macrophages51. Different models describe the targeting of chromatin remodeling machines to 
their site of action, i.e. acetylated histones that target and stabilize the SWI-SNF complex at 
target loci52. Very recently another report confirmed that small hairpin RNA–mediated 
knockdown of the endogenous ARTD1 expression resulted in reduced IL-12p40 mRNA 
expression and Il12b promoter activity53. BMDM from ARTD1–deficient mice had also 
decreased IL-12p40 expression at both mRNA and protein levels. 
 IL-12 is a cytokine that connects innate and adaptive immune responses either 
indirectly via NK cell activation or directly by activating CD4 and CD8 T cells7. In this study, 
we observed a reduced NK cell activation during sepsis in Artd1∆Myel compared to Artd1flox/flox 
mice. Our data suggests that ARTD1 deficient macrophages fail to activate NK cells via IL-12 
expression, ultimately leading to decreased IFN-γ serum levels and thus protecting against an 
acute LPS-induced sepsis. Several lines of evidence suggest that NK cells might be involved 
in key functions during sepsis41. Similar to ARTD1 knock-out mice, antibody mediated NK 
cell depletion in vivo protected against LPS-induced shock and significantly decreases IFN-γ 
cytokine levels26,54. NK cells promote and particularly amplify as very early and main 
producers of IFN-γ during sepsis the inflammatory response. Today, NK cells represent 
promising targets for novel approaches in sepsis therapy41.  
 Reduced NK cells activation significantly reduces the speed of pathogen clearance 
during sepsis41. Thus, by enhancing Il12b expression in macrophages ARTD1 also contributes 
to a potent immune response to pathogens. This was very obvious in the second disease 
model we investigated. Previous studies characterized the stomach under basal conditions to 
be a predominantly myeloid organ with little or no lymphocyte contribution42. Myeloid cells 
centrally function as initiators of immune responses against pathogens. Our study revealed 
that ARTD1 deficient macrophages recruit equal numbers of CD4 T cells during gastric H. 
pylori infections into the stomach than their wild-type counterparts, but lead to a significantly 
decreased TH1 CD4 T cell polarization. The decreased IFN-γ expression explains the 
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increased H. pylori colonization of the stomach. Thus, ARTD1 limits pathogen spreading via 
IL-12 and the initiation of potent immune responses, but is also involved in the fine balance 
of maintaining tissue homeostasis while efficiently controlling invading pathogens. 
 Macrophages play important yet bimodal roles in orchestrating tumor associated 
immune responses43. On the one hand side they are involved in tumor killing and other 
effector functions, but they can also promote tumor growth by skewing and suppressing T cell 
responses. Our data suggests ARTD1 to function as the latter one. First, ARTD1 deficient 
macrophages do not infiltrate the tumor as efficient as ARTD1 proficient do (Figure 4B). In 
addition, their activation status is significantly reduced displayed by reduced TNF-α 
expression. The fact that we identified many cell adhesion molecules to be significantly lower 
expressed in ARTD deficient macrophages (Figure 1C) could explain the impaired 
recruitment to the site of action. Nevertheless, both ARTD1 pro- and deficient macrophages 
recruited equally CD4 and CD8 T cells to the MC-38 tumor, xenograft but their activation 
was significantly decreased, indicating that ARTD1 in macrophages maintains the activation 
of TH1 immune responses also during tumor formation, thereby limiting tumor growth. 
 Taken together we identified ARTD1 in macrophages as critical regulator of pro-
inflammatory cytokine expression. In particular, ARTD1 ensures the initiation of several 
potent immune responses to react against LPS or to eliminate pathogens and tumors in vivo. 
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Material and Methods 
Animals and Animal Experiments 
The conditional Artd1 allele in ESCs as well as the generation of the Artd1flox/flox mice was 
performed by Polygene as described55. Briefly, the vector from EUCOMM (targeting project 
45261) was electroporated in C57Bl/6 ES cells and analyzed by PCR. Correctly integrated ES 
cell clones were injected into blastocysts resulting in chimeric mice. Subsequent mating of the 
chimeric mice with the Flp-deleter mice resulted in the Flp-mediated deletion of the gene trap 
cassette and leaving only the loxP flanked exon 4 of Artd1. To generate whole-body Artd1 
knock-out mice (Artd1del/del) the generated Artdflox/flox mouse strain was crossed to the CMV-
Cre deleter strain (provided by R. Santoro). Myeloid specific Artd1 knock-out mice 
(Artd1∆Myel) were generated by crossing Artd1foxl/flox mice to LyzM-Cre (The Jackson 
Laboratory, strain 004781) mice. For all experiments 6-12 week old, age and sex matched 
mice were used. LPS (Escherichia coli O111:B4, Sigma-Aldrich) was injected i.p. at a 
concentration of 4 mg per kg bodyweight.  
 Helicobacter pylori infections were performed as described42. Briefly, Mice were 
infected orally on 2 consecutive days with 108 colony-forming units (CFUs) H. pylori PMSS1 
and analyzed at 1 and 3 months p.i. unless specified otherwise. The subcutaneous MC38 
tumor model was performed as described earlier56. Briefly, Colon adenocarcinoma cells (MC-
38, 0.5x106 cells in 100 µl phosphate buffered saline) were injected subcutaneously (s.c.) into 
the flanks and tumor progression was determined by caliper measurements every second day. 
After two weeks, mice were sacrificed, tumors were weighed and the volume was calculated 
using the formula (a2 × b)/2, where a constitutes the shorter and b the longer dimension of the 
tumor. 
 All animals were housed in pathogen free conditions at the University of Zurich. All 
animal experiments were carried out in accordance with the Swiss and EU ethical guidelines 
and have been approved by the local animal experimentation committee of the Canton Zurich 
under licenses 207/2015 and 266/2014. 
 
Cell Culture and reagents 
Murine bone marrow derived macrophages (BMDM) were generated as previously 
described57 and maintained in RPMI1640 supplemented with 10 % fetal calf serum, 5 % 
penicillin/streptamycin and 20 ng/ml recombinant murine M-CSF (Preprotech). 
Thioglycollate (Sigma-Aldrich) elicited murine peritoneal macrophages were isolated as 
described58. Cell culture grade LPS (Escherichia coli O111:B4) was purchased from Sigma-
Aldrich and recombinant murine interferon gamma from Preprotech. The PARP inhibitors 
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PJ34 and Olaparib were purchased from Selleckchem. MC-38 cells were cultured as 
described56. 
 
ELISA 
Whole blood serum of mice and cell culture supernatant of BMDM was analyzed by 
ProcartaPlex Immunoassay (ThermoFisher) according to the protocol and measured on a Bio-
Plex instrument (Bio-Rad). 
 
Flow cytometry 
Flow cytometrical analyses of spleens, tumors and stomach tissue were performed as 
described earlier42. Briefly, tumors were cut into pieces and digested with 15 mM HEPES, 
500 U/ml of type IV collagenase (Sigma-Aldrich) and 0.05 mg ml−1 DNase I in RPMI-1640 
medium with 10% fetal bovine serum and 100 U ml−1penicillin/streptomycin shaking at 37°C 
for 60 min. Subsequently, the samples were pushed through a cell strainer (70µm) using a 
syringe plunger. Single cell suspensions were stained with the respective antibodies and 
analyzed on LSR Fortessa (BD Bioscience). 
 
RNA sequencing and bioinformatic analysis 
For the library preparation the quality of the isolated RNA was determined with a Qubit® 
(1.0) Fluorometer (Life Technologies) and a Bioanalyzer 2100 (Agilent). Only those samples 
with a 260 nm/280 nm ratio between 1.8–2.1 and a 28S/18S ratio within 1.5–2 were further 
processed. The TruSeq RNA Sample Prep Kit v2 (Illumina) was used in the subsequent steps. 
Briefly, total RNA samples (100-1000 ng) were poly-A enriched and then reverse-transcribed 
into double-stranded cDNA. The cDNA samples were fragmented, end-repaired and 
polyadenylated before ligation of TruSeq adapters containing the index for multiplexing. 
Fragments containing TruSeq adapters on both ends were selectively enriched with PCR.  The 
quality and quantity of the enriched libraries were validated using Qubit® (1.0) Fluorometer 
and the Caliper GX LabChip® GX (Caliper Life Sciences). The product is a smear with an 
average fragment size of approximately 260 bp. Library DNA concentrations were 
normalized to 10 nM in Tris-Cl 10 mM, pH8.5 with 0.1% Tween 20. 
 Cluster generation and sequencing were performed using the TruSeq PE Cluster Kit 
HS4000, or the TruSeq SR Cluster Kit HS4000 (Illumina) was used for cluster generation 
using 2 nM of pooled normalized libraries on the cBOT. Sequencing were performed on the 
Illumina HiSeq 4000 paired end at 2 x 150 bp or single end 125 bp using the TruSeq SBS Kit 
HS4000 (Illumina).  
 Reads were quality-checked with FastQC. Sequencing adapters were removed with 
Trimmomatic59. Subsequently, reads of at least 20 base length, and with an overall average 
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phred quality score greater than 10 were aligned to the reference genome and transcriptome of 
Mus Musculus (FASTA and GTF files, respectively, downloaded from GRCm38) with STAR 
v2.5.160 with default settings for single end reads.  
 Distribution of the reads across genomic isoform expression was quantified using the 
R package GenomicRanges61 from Bioconductor Version 3.0. Differentially expressed genes 
were identified using the R package edgeR62 from Bioconductor Version 3.0.  A gene is 
marked as differentially expressed (DE) if it possesses the following characteristics: (1) at 
least 10 counts in at least half of the samples in one group; (2) p <= 0.05; (3) fold change >= 
1.5. 
 
RNA extraction and quantitative real time PCR (qPCR) analysis. 
RNA isolation and qPCR were performed as described63. Briefly, RNA extraction was 
performed with the NucleoSpin RNA II kit (Macherey-Nagel). RNA was quantified with a 
NanoDrop and reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) according to the supplier’s protocol. qPCRs were performed with the 
SYBR green KAPA SYBR® FAST (Sigma-Aldrich) and a Rotor-Gene Q 2plex HRM system 
(Qiagen). See Table S1 in the supplemental material for primer sequences. The relative 
amounts of each mRNA were normalized to the Rps12.  
 
Westernblot 
Western blotting was performed as described64. For western blot analysis, proteins were 
separated by SDS-PAGE, and bands were visualized using the Odyssey infrared imaging 
system (LI- COR). Antibodies used for western blotting were anti-PARP-1 (1:1000, Santa 
Cruz sc-7150) and anti-Tubulin (1:10,000, Sigma, #T6199). 
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Table 1. Genotyping primer 
Gene Forward primer Reverse primer 
floxed 
Artd1 
GCTTCTACTACCTCCCAAGAAA
GAGCG 
GGCTTTAGTGTGGCAACTTATCCC 
Artd1 
localizat
ion 3` 
CACTGAACTGTCTCCTTAGCCA
ACTCTGC 
GGAACTTCGGAATAGGAACTTCGG
TTCC 
Artd1 
localizat
ion 5` 
CTAGGATTCTGTGTCTTGACCA
TGCACTTG 
CGTATAGCATACATTATACGAAGTT
ATGTCGAG 
Deleted 
Artd1 
GCTTCTACTACCTCCCAAGAAA
GAGCG 
CCTCTGCTGCGTGACTAAGGC 
 
Table 2. qPCR Primer 
Gene Forward Primer Reverse Primer 
Il12b GAAGTTCAACATCAAGAGCAGTAG AGGGAGAAGTAGGAATGGGG 
Cxcl3 ACCCAGACAGAAGTCATAGCC ACACATCCAGACACCGTTGG 
Cd55 CGGGCAAGGTCTCTTCTACC CAGTCTCCGCGTACAGTTGG 
Il23a ACCAGCGGGACATATGAATCT AGACCTTGGCGGATCCTTTG 
Itgax GCAGACACTGAGTGATGCCA TCGGAGGTCACCTAGTTGGG 
Socs1 CCGCCAGATGAGCCCAC GGTTGCGTGCTACCATCCTA 
Il18 ATGCTTTCTGGACTCCTGCC ATTGTTCCTGGGCCAAGAGG 
Il6 CCAATTTCCAATGCTCTCCT ACCACAGTGAGGAATGTCCA 
Tnfa GTCGTAGCAAACCACCAAGTGG GAGATAGCAAATCGGCTGACGG 
Ifng CCTTCTTCAGCAACAGCAAGGCGA TGGACCTGTGGGTTGTTGACCTCA 
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Figure legends: 
Figure 1: ARTD1 regulates IL-12/IL-18 gene expression in BMDM in an enzymatic 
independent manner  
A) Targeting strategy for the generation of the Cre-mediated whole body ARTD1-
deficient mouse (adapted from Skarnes, Rosen et al. 2011). Cre-mediated 
recombination deletes Exon 4 of the Artd1 gene. 
B) RNA-sequencing of total RNA extracted from Artd1flox/flox and Artd1del/del BMDM 
either left untreated or treated with 10 ng/ml LPS and 2 ng/ml INF-γ for 4 h. All 
LPS/IFN- γ-induced genes (approx. 2500 genes) (fold-change ≤ 2, P < 0.05) were 
clustered. 
C) Up-regulated genes identified in B) were clustered to identify ARTD1 co-activating 
and co-repressing function. 
D) Quantitative Real-time PCR analysis of selective co-activated and co repressed genes 
in Artd1flox/flox and Artd1del/del BMDM identified in C. Data presented as mean + SD of 
three biological replicates. t-Test: *P < 0.05, **P < 0.01 
E) Gene enrichment analysis of all significantly LPS/IFN- γ-induced genes (left panel, 
identified in B), ARTD1 co-activated and ARTD1 co repressed genes (middle and 
right panel, identified in C) in Artd1flox/flox and Artd1del/del BMDMs.  
F) ELISA of cell culture supernatants for the quantification of the indicated cytokines 
produced by Artd1flox/flox and Artd1del/del BMDM, respectively, stimulated with 10 
ng/ml LPS and 2 ng/ml INF-γ for 18 h. Data presented as mean concentration + SD of 
three independent experiments. t-Test: *P < 0.05, **P < 0.01 
 
Figure 2: Myeloid-specific depletion of ARTD1 reduces the LPS-induced IL-12/IFN-γ 
signaling in vivo 
A) Targeting strategy for the generation of myeloid specific ARTD1 knock-out mouse 
(adapted from Skarnes, Rosen et al. 2011). Cre-mediated recombination deletes Exon 
4 of the Artd1 gene. 
B) Artd1flox/flox and Artd1ΔMyel mice were intraperitoneally injected with PBS or 4 mg/kg 
of LPS. After 4 h whole blood serum was collected and the levels of selected 
cytokines were quantified by Luminex ELISA. Data shown as mean ± SEM of three 
independent experiments. t-Test: *P < 0.05 
C) Artd1flox/flox and Artd1ΔMyel mice were intraperitoneally injected with PBS or 4 mg/kg 
of LPS. After 4 h total spleen tissue was isolated and indicated gene expression 
quantified by qPCR. Data shown as mean ± SEM of three independent experiments. 
t-Test: *P < 0.05, **P < 0.01 
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D) Intracellular cytokine staining of splenocytes from Artd1flox/flox and Artd1ΔMyel mice 
intraperitoneally injected with either PBS or 4 mg/kg of LPS. After 4 h, intracellular 
INF-γ was detected by flow cytometry and positively stained NK-, CD4 T- and CD8 
T cells were quantified. Data shown as mean ± SEM of two independent experiments. 
t-Test: *P < 0.05. 
E) ELISA for IFN-γ secreted from MACS-sorted NK cells isolated from of Artd1foxl/flox 
and Artd1ΔMyel mice. NK cells were stimulated with recombinant murine IL-12p70 for 
18 hrs and cell culture supernatant was analyzed. 
 
Figure 3: ARTD1 controls Helicobacter-associated T cell–driven immunopathology 
A) H. Pylori or PBS were orally administrated to Artd1flox/flox and Artd1ΔMyel mice. After 4 
weeks gastric homogenates were streaked out and the colony forming unit were 
determined. 
B) In the stomach of the same mice as in A, CD4 T cell infiltration was flow 
cytometrically determined. 
C) Intracellular cytokine staining for IFN-γ and IL-17 in gastric CD4 T cells (determined 
in B) 
 
Figure 4:  ARTD1 controls macrophage infiltration and CD4/CD8 T cell activation in 
tumors 
A) Tumor growth of MC-38 cells subcutaneously injected into the flanks of Artd1flox/flox 
and Artd1ΔMyel mice was determined by caliper measurements after 6 and after 14 
days. 
B) Infiltration and TNF-α expression of macrophages in the tumors grown within 
Artd1flox/flox and Artd1ΔMyel mice were flow cytometrically determined. 
C) Infiltration, IFN-γ and TNF-α expression of CD4 T cells in the tumors grown within 
Artd1flox/flox and Artd1ΔMyel mice  were flow cytometrically determined. 
D) Infiltration, IFN-γ and TNF-α expression of CD8 T cells in the tumors grown within 
Artd1flox/flox and Artd1ΔMyel mice  were flow cytometrically determined. 
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Supplementary Figure 1 
A) Successful modification of the Artd1 locus. To verify the integration of the targeting 
vector at the Artd1 locus on chromosome 1, a long range PCR amplifying the 3`and 
5`homolgy arm of the Artd1 gene was performed on genomic DNA from the initial 
breeding pair. Embryonic stem cell DNA used for the blastocyst injection served as 
control. Size of the bands are indicated as base pairs (bp). 
B) PCR amplification of mouse genomic DNA of Artd1flox/wt, Artd1wt/wt, and Artd1flox/flox 
mice. Size of the bands are indicated as base pairs (bp). 
C) Westernblot analysis of the indicated organs for ARTD1 expression in Artdwt/wt, 
Artd1del/del and Artd1wt/delmice. 
D) Necropsy analysis of three Artd1flox/flox and two , Artd1del/del male mice of 8 weeks. 
Body weights as well as indicated organ weights were determined. 
E) Quantitative Real-time PCR analysis of Artd1 expression in Artd1flox/flox and Artd1del/del 
BMDM, respectively. 
F) RNA-sequencing of total RNA extracted from Artd1flox/flox and Artd1del/del BMDM 
either left untreated or treated with 10 ng/ml LPS and 2 ng/ml INF-γ for 4 h. All 
LPS/IFN- γ-repressed genes (approx. 3000 genes) (fold-change ≤ 2, P < 0.05) were 
clustered. 
G) RNA-sequencing of PARPi BMDMs 
H) ELISA of cell culture supernatant for the quantification of the indicated cytokines 
from Artd1flox/flox and Artd1del/del BMDMs. Cells were treated either with DMSO or 5 
µM PARPi (PJ34/Olaparip) prior to stimulation with 10 ng/ml LPS and 2 ng/ml INF-
γ for 18 h. Data presented as mean concentration + SD of three independent 
experiments. 
 
Supplementary Figure 2 
A) Western blot analysis of BMDM and thioglycolate elicited peritoneal macrophages 
from Artd1flox/flox and Artd1ΔMyel mice. ARTD1 levels were quantified in whole cell 
lysates. Tubulin was used as loading control. 
B) Artd1flox/flox and Artd1ΔMyel mice were intraperitoneally injected with PBS or 4 mg/kg 
of LPS. After 4 h whole blood serum was collected and the levels of selected 
cytokines were quantified by luminex ELISA. Data shown as mean ± SEM of three 
independent experiments. t-Test: *P < 0.05 
C) Immunophenotyping of the spleen from Artd1flox/flox and Artd1ΔMyel mice. Spleen single 
cell suspensions were stained with fluorescently labeled antibodies and cell counts 
were determined by flow cytometry.  
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1. Obtained data related to aim 2: 
To investigate whether and in which cell type ADP-ribosylation inhibitors (i.e. Talazoparib or 
Olaparib) affect proinflammatory signaling. 
1.1. Co-treatment of wild type animals with LPS and PARP inhibitors reduce different 
cytokines in the serum 
ADP-ribosylation regulates different DAMP-mediated inflammatory conditions such as 
ischemia-reperfusion-induced necrosis, but also PAMP-mediated inflammations such as 
bacterial infections180. First-generation PARPi reduce the burden in LPS-induced 
inflammatory models166,213. Although these unspecific first generation PARPi lack enzyme 
specificity, LPS-induced endotoxic shock resistant ARTD1 knock-out mice77 emphasize that 
ARTD1 is the major ADP-ribosylating enzyme contributing to systemic bacterial infections. 
The expression of soluble mediators during infections activates and primes host cells to 
orchestrate pathogen elimination163. To gain insights about ADP-ribosylation, particularly 
ARTD1-dependent cytokine expression, during LPS-induced sepsis in vivo, we treated wild-
type mice with Dimethylsulfoxide (DMSO) or the most specific ARTD1 inhibitor available 
(Olaparib, 5 mg/kg) for 1 h. Subsequently, the animals received 4 mg/kg LPS and 
proinflammatory mediators were enzyme-linked immunosorbent assay (ELISA)-quantified in 
blood serum after additional 4 hrs (Figure 7). Animal conditions (lethargy, mobility) strongly 
suggested the induction of a severe inflammation. In addition, we could determine 
significantly reduced IFN-γ, IL-18, IL-6 and TNF-α, but not IL-12p70 levels in Olaparib 
treated mice compared to the DMSO treated mice.  
Figure 7. PARPi inhibit proinflammatory cytokine expression during LPS-induced sepsis. ELISA 
quantified IFN-γ, IL-12p70 IL-18, IL6 and TNF-α in blood serum. Wild-type mice were i.p. injected 
with either DMSO or 5 mg/kg Olaparib. After 1 h, mice received i.p. 4 mg/kg LPS. After 4 h, the mice 
were sacrificed, whole blood was obtained by cardiac puncture and serum was isolated. Levels of 
selected cytokines were quantified by luminex ELISA. Data shown as mean ± SEM. t-Test: *P < 0.05 
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The data suggests anti-inflammatory actions of PARPi during LPS-induced sepsis. However, 
the responsible cell type for the observed effect remains elusive. In addition, Olaparib also 
inhibits other ARTD1 family members (i.e. ARTD2), thus determining the responsible ARTD 
family member to inhibit inflammatory cytokine expression needs further investigations. 
1.2. NK cells are PARPi sensitive 
NK cells are lymphocyte cells that belong to the innate immunity and were initially described 
for their ability to kill leukemic cells without prior sensitization214. Circulating NK cells make 
up approximately 4-15% of blood lymphocytes and are in a resting phase. Upon activation by 
cytokines such as IL-12, IL-18 or IL-15, NK cells infiltrate pathogen infected or malignant 
tissue and carry out cytotoxic functions215. In contrast, NK cells in peripheral tissues such as 
tonsils lymph nodes and spleen are activated by dendritic cells via cell-to-cell contact and via 
the abovementioned cytokines. Activated NK cell secrete high levels of IFN-γ, TNF-α or 
GM-CSF to amplify the inflammatory response and particularly activate T cells215. The fact 
that pharmacologic inhibition of ADP-ribosylation protects against different diseases, in 
particular against septic shock, motivated us to identify the cell type that would account for 
the observed protection. During sepsis, NK cells are the very early and main producers of 
IFN-γ, thereby priming and amplifying the hosts inflammatory response216.  
 To identify the main PARPi sensitive cell type that was responsible for the observed 
differences in the serum cytokine levels (Figure 7), isolated splenocytes of wild-type mice 
were treated for 1 h with control buffer, 5 µM Olaparib or 25 nM Talazoparib prior the 
stimulation with 0.1 µg/ml LPS for 18 hrs. Quantification of secreted IFN-γ levels by ELISA 
revealed a significant LPS-induced IFN-γ induction, which was significantly reduced by both 
Olaparib and Talazoparib (Figure 8A).  
Figure 8. The IL-18 signaling pathway in NK cells is PARPi sensitive. ELISA quantification of cell 
culture supernatant for IFN-γ. (A) Splenocyte suspensions of wild type mice were either left untreated 
or incubated with 5 µM Olaparib or 25 nM Talazoparib for 1 h and subsequently stimulated with  
0.1 µg/ml LPS for 18 h. (B) MACS sorted NK cells of wild type mice were either left untreated or 
incubated with 5 µM Olaparib or 25 nM Talazoparib for 1 h and subsequently stimulated with 10 ng/ml 
IL-12p70 or 10 ng/ml IL-18 for 18 h. 
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NK cell mediated IFN-γ expression relies on innate immune cell secretion of IL-12 and/or IL-
18. Earlier studies provided evidence that proinflammatory cytokine expression of e.g. 
macrophages do not depend on ARTD1 catalytic activity, but on the protein itself72 (and the 
prepared manuscript in section 3). Hence, the provided data suggested that the differential 
IFN-γ expression levels are indeed regulated by ADP-ribosylation and that NK cells might be 
mainly sensitive to PARPi treatment.  
 To directly address the question whether NK cell-mediated IFN-γ expression is 
enzymatically dependent on ADP-ribosylation, we sorted NK cells of wild type mice by 
magnetic-activated cell sorting (MACS) and confirmed NK cell purity being between 80-90 
% (data not shown). Enriched NK cells were subsequently either left untreated or incubated 
with 5 µM Olaparib or 25 nM Talazoparib for 1 h prior the stimulation with either 10 ng/ml 
IL-12p70 or 10 ng/ml IL-18 for 18 h (Figure 2B). ELISA Quantification of the IFN-γ levels 
for both treatments (i.e. IL-12p70 and IL-18 treated NK cells) revealed a significant increase 
of IFN-γ by both cytokines, however to a different extent: IL-18 was about twice as potent to 
induce IFN-γ in NK cells in vitro as compared to IL-12p70. Very interestingly, PARPi 
reduced only IL-18, but not IL-12p70-induced IFN-γ in NK cells, suggesting that the IL-18 
signaling pathway in NK cells is sensitive to PARPi and that this is the case for both tested 
inhibitors (i.e. Olaparib and Talazoparib). It is currently not known which ARTD family 
member might contribute to the PARPi sensitivity in NK cells. Mechanistically, IL-18 
signaling involves, comparable to LPS stimulation, the transcription factor NF-κB for the 
transcriptional regulation of IL-18-induced target genes (i.e. IFN-γ). Given that ARTD1 is a 
known co-factor of NF-κB, these findings might suggest that ARTD1 functions in a cell type 
dependent manner; either via its scaffolding ability (i.e. only dependent on the protein) in 
macrophages and fibroblasts72, or via its enzymatic activity in NK cells. Further in vivo 
experiments are planned to investigate the PARP inhibitor sensitivity in NK cells, for 
example by the generation of ARTD1-specific NK cell knock-out mouse. 
2. Obtained data related to aim 3: 
To identify additional ARTD family members involved in the LPS-induced inflammatory signaling 
response in fibroblasts. 
2.1. Several ARTD family members control LPS-induced proinflammatory gene 
expression in fibroblasts 
Since the discovery of low potency PARPi like 3-AB, their development greatly enhanced the 
inhibitor’s specificity towards the ARTD family. Nevertheless, PARPi profiling revealed that 
the currently available PARPi lack specificity towards a distinct ARTD family member148. 
Besides inhibiting the growth of BRCA deficient tumor cells, PARPi have also been described 
to exert anti-inflammatory effects, which could additionally account for their anti-tumorigenic 
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effects81,135,149. This raised the question whether other ARTD family members could 
contribute to the anti-inflammatory effects of PARPi as well. Along this line our lab provided 
strong evidence for the transcriptional cofunction of ARTD1 in NF-κB-dependent gene 
expression72. 
 To identify ARTD family members possibly regulating NF-κB mediated 
proinflammatory signaling, a siRNA screen was performed. Mouse lung fibroblast (MLF) 
cells were transfected with siRNAs against all 17 murine ARTDs and stimulated with  
0.1 µg/ml LPS for 4 hrs. Total RNA was extracted and reverse transcribed into cDNA to 
quantify by quantitative real-time PCR (qRT-PCR) the expression of Cxcl10, a primary NF-
κB target gene217 (Figure 9).  
 
Figure 9. ARTD family members differentially regulate NF-κB dependent gene expression in 
fibroblast cells. Quantitative RT-PCR analysis of mouse lung fibroblast transfected with siMock and 
siRNAs against all 17 murine ARTD family members. After 48 hrs, the cells were stimulated with 0.1 
µg/ml LPS for 4 hrs, total RNA was extracted, reverse transcribed and Cxcl10 expression was 
determined by qRT-PCR. The red line indicates the expression level in LPS-treated siMock fibroblasts. 
 
The extensive LPS-induced up-regulation of Cxcl10 in siMock transfected MLFs confirmed 
the successful stimulation of the cells. While knock-down of ARTD4, ARTD12 and ARTD13 
lead to enhanced Cxcl10 expression compared to siMock, knock-down of ARTD2, ARTD3, 
ARTD11, ARTD14, ARTD15 in contrast reduced the Cxcl10 expression, although to 
different extents. These experiments revealed that loss of these latter ARTD family members 
reduce LPS-induced Cxcl10 expression in fibroblast, suggesting that they might function as 
NF-κB co-factors. Surprisingly knockdown of ARTD1 did not affect Cxcl10 gene expression 
under the tested conditions. This could be due to compensatory mechanisms in the used 
mouse lung fibroblast cell line or that Cxcl10 is not regulated by ARTD1.  
2.2. ARTD11 selectively enhances proinflammatory cytokine expression of Cxcl2 and 
Cxcl10 but not Il6 in fibroblasts 
Since siARTD11 attenuated Cxcl10 expression to the strongest extent, its involvement in NF-
κB-dependent gene expression was further investigated. To this end, the expression of 
additional NF-κB target genes was analyzed in an ARTD11-dependent manner at two 
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different time points after stimulation. siMock and siARTD11 transfected MLFs were 
stimulated with 0.1 µg/ml LPS for 1 hr or 4 hrs. Subsequently, the expression of the classical 
primary NF-κB response genes Cxcl10, Cxcl2 and the secondary NF-κB response gene Il6 
were quantified by qPCR (Figure 10)218. Successful siRNA mediated knock-down of 
ARTD11 selectively reduced the LPS-induced expression of the proinflammatory mediators 
Cxcl10 and Cxcl2 (for the latter however not to a statistically significant extent due to high 
variation), while the expression of Il6 was not affected.  
 
Figure 10. ARTD11 enhances Cxcl10 and Cxcl2, but not Il6 expression in fibroblast cells. 
Quantitative RT-PCR analysis of mouse lung fibroblast transfected with siMock and ARTD11. After 
48 hrs, the cells were stimulated with 0.1 µg/ml LPS for 1 hr and 4 hrs, total RNA was extracted, 
reverse transcribed and Artd11, Il6, Cxcl10 and Cxcl2 expression was determined by qRT-PCR. Data is 
normalized over untreated and presented as mean + SD of three biological replicates. t-Test:  ***P < 
0.001. 
 
The expression inhibition (%) of Cxcl2 and Cxcl10 was comparable, although Cxcl2 was 
induced ten times stronger by LPS compared to Cxcl10. These data indicated that ARTD11 
specifically regulates the expression of only a subset of proinflammatory cytokines (i.e. the 
primary target genes) rather than functioning as a general NF-κB co-regulator. 
2.3. ARTD11 does not enhance proinflammatory cytokine expression in macrophages. 
Although different cell types express the same proinflammatory cytokines, their underlying 
molecular expression mechanisms might differ, depending on the cell type219. To test whether 
ARTD11 regulates proinflammatory gene expression also in a different cell type, we repeated 
the above-described experiments with primary macrophages. Since primary macrophages are 
difficult to transfect and in the meantime ARTD11 deficient (-/-) mice were available, bone 
marrow derived macrophages (BMDM) from Artd11+/+ and Artd11-/- mice (see below) were 
generated, stimulated with 10 ng/ml LPS for 1 hr or 4 hrs and gene expression of Cxcl10, 
Cxcl2 and Il6 analyzed by qRT-PCR. Although LPS treatment induced all defined NF-κB 
target genes, the knock-out of ARTD11 in macrophages did not alter their gene expression 
(Figure 11). 
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Figure 11. ARTD11 does not regulate Il6, Cxcl10 or Cxcl2 in macrophages. Quantitative RT-PCR 
analysis of primary bone marrow derived macrophages from ARTD11+/+ and ARTD11-/- mice. After 5 
days of differentiation, the cells were stimulated with 1 ng/ml LPS for 1 hr and 4 hrs, total RNA was 
extracted, reverse transcribed and Artd11, Il6, Cxcl10 and Cxcl2 expression was determined by qRT-
PCR. Data is normalized over untreated ARTD11+/+. 
 
The data thus suggests, that ARTD11 enhances Cxcl10 and Cxcl2 proinflammatory gene-
expression in a cell type specific manner (i.e. in fibroblast cells but not in macrophages). The 
Artd11-/- BMDM thus likely evolved compensatory mechanisms during their development to 
overcome the lack of ARTD11 for LPS induced gene expression, although additional genes 
should be analyzed to strengthen this conclusion. 
2.4. ARTD11 acts downstream of NF-κB nuclear translocation 
ARTD11 could affect NF-κB function at different levels. To assess whether ARTD11 alters 
the NF-κB nuclear translocation, NF-κB was monitored by immunofluorescence in 
siARTD11 or siMock treated MLFs stimulated for 30 min with LPS. After 30 min LPS, the 
large subunit of NF-κB translocated to the nucleus, independently of whether ARTD11 was 
expressed or knocked down. This indicates that ARTD11 itself does not regulate 
cytoplasmatic LPS signaling events, but rather regulates NF-κB target gene expression at the 
chromatin or at the post-transcriptional level (Figure 12).  
Figure 12. ARTD11 does not regulate LPS-induced NF-κB nuclear translocation. 
Immunofluorescent analysis of mouse lung fibroblast cells transfected with siMock and ARTD11. 
After 48 hrs, the cells were stimulated with 0.1 µg/ml LPS for 30 mins and formaldehyde fixed. The 
localization of p65 (red) was determined by staining with a respective antibody. The nucleus was 
counterstained with DAPI (blue). 
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2.5. ARTD11 localizes to the nuclear envelope. 
The functional analysis of proinflammatory gene expression and the unchanged p65 
translocation in ARTD11 deficient cells strongly indicated, that ARTD11 regulates NF-κB 
after its nuclear translocation (see 2.2 and 2.4). Previous reports described a nuclear envelope 
localization for ARTD11220. To gain additional mechanistic insights about the molecular 
function of ARTD11 during its transcriptional regulation of Cxcl2 and Cxcl10, the 
localization of ARTD11 was further investigated. Due to the lack of suitable antibodies, 
ARTD11 was overexpressed as a green fluorescent protein (GFP)-tagged fusion protein in 
HEK293T cells. Immunofluorescent analyses confirmed the previous report and the 
localization of ARTD11 at the nuclear envelope (Figure 13A/13B). Further investigations are 
necessary to specify ARTD11 localization at the inner or outer nuclear membrane.  
 
Figure 13. ARTD11 localizes to the nuclear envelope. Immunofluorescent analysis of HEK293T 
cells transfected with murine ARTD11-eGFP constructs. After 48 hrs, the cells were formaldehyde 
fixed and the localization of ARTD11 (green) was determined by fluorescent microscopy (A). Z-stack 
images were acquired by confocal microscopy (B). The nucleus was counterstained with DAPI (blue). 
2.6. Artd11-/- mice develop normally 
To learn more about the role of ARTD11 in a whole organism in steady state, we performed 
phenotyping of Artd11-/- mice. Previous publications reported a role of ARTD11 during 
spermatogenesis resulting in infertility of Artd11-/- male mice220. After successful generation 
of male and female Artd11-/- mice, their breeding resulted in no offspring. In contrast, female 
Artd11-/- and male Artd11+/- mice breed normally with regular litter sizes. Having confirmed 
the infertility phenotype, Artd11-/- mouse development was analyzed by necropsy in 
collaboration with Dr. Giovanni Pellegrini (Pathology, Vetsuisse Faculty, UZH). The whole 
body weights of two Artd11+/+ and three Artd11-/- male mice of 8 weeks as well as the 
weights of some selected organs (brain, heart, kidney, liver, spleen and testis) were measured 
and the tissue composition assessed by immunohistochemical analyses. The analysis revealed 
neither macroscopic nor microscopic differences between the analyzed genotypes (Figure 14; 
data not shown).  
A	
overlay ARTD11-eGFP 
B	
ARTD11-eGFP 
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Figure 14. ARTD11 knock-out mice develop normal and do not show phenotypic differences to 
wild-type littermates. Necropsy analysis of three Artd11-/- and two Artd1+/+ male mice of 8 weeks. 
Body weights as well as indicated organ weights were determined. 
 
To investigate whether the development of immune cells was affected by ARTD11 knock-
out, a immunophenotyping of the splenic immune compartment in four Artd11+/+ and five 
Artd11-/- was performed (collaboration with Juliana Komuczki, Institute of Experimental 
Immunology, UZH). Single cell suspensions of the spleen were stained with specific 
antibodies and the cell populations quantified by flow cytometry (Figure 15).  
Figure 15. ARTD11 knock-out mice do not have significant differences in the cellular 
composition of the spleen. Immunophenotyping of four ARTD11+/+ and five ARTD11-/- male mice. 
Single cell suspensions of the spleen were stained with the respective antibodies and cell numbers were 
acquired by flow cytometry. Data presented as % of CD45+ cells. 
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No significant differences between Artd11+/+ and Artd11-/- mice were identified, suggesting 
that under basal conditions, apart from the published infertility, Artd11+/+ and Artd11-/- mice 
do not show any other phenotypic difference. We are currently performing inflammation 
models that are mainly based on the fibroblast reaction (PMA into ear) to further validate the 
functional role of ARTD11 in inflammation. 
3. Other data (not related to aims)  
3.1. The generation of a tamoxifen-inducible ARTD1 deficient mouse 
The options for studying ARTD1 gene function in vivo are currently limited when using the 
classical Artd1-/- mouse generated by Zhao-Qi Wang221. Although ARTD1 plays important 
functions during DNA repair it is not essential for murine development222. Interestingly, the 
Artd1/2 double knock-out is embryonically lethal13, suggesting a compensatory mechanism(s) 
and partially overlapping function of ARTD1 and ARTD2. To further investigate this 
hypothesis and specifically to investigate whether double deficiency of Artd1/2 is only 
important during development or also during adulthood we generated first an tamoxifen-
inducible Artd1-/- strain with the plan to cross this strain later into the Artd2-/- strain, allowing 
us to delete ARTD1 in these mice (but also in isolated cells) at any desired time-point.  
 To generate the tamoxifen-inducible Artd1-/- strain we crossed Artd1flox/flox mice with 
B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj from the Jackson Laboratory (Strain ID #008463). 
Having generated the strain (genotyping results not shown) we next assessed the 
recombination efficiency in vivo. Three mice received 1 mg tamoxifen by i.p. injection for 
five consecutive days. Similarly, two control animals were vehicle-treated (PBS). Ten days 
after the last tamoxifen administration, the mice were euthanized and lung, liver, spleen and 
testis were isolated. Whole cell protein extracts were generated and 150 µg of protein loaded 
on a SDS-PAGE gel. ARTD1 levels were quantified by Western Blot using tubulin as a 
loading control (Figure 16).  
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Figure 16. Tamoxifen administration to Rosa26-CreERT2+ Artd1flox/flox mice efficiently deletes 
Artd1. One milligram Tamoxifen or PBS (vehicle) was administrated i.p. into Rosa26-CreERT2+ 
Artd1flox/flox mice for five consecutive days. Whole cell lysates (150 µg protein) of the indicated organs 
were subjected to Western Blot analysis and stained with antibodies against ARTD1 or tubulin. 
 
In all analyzed tissues, ARTD1 levels markedly decreased upon tamoxifen administration, 
although tissue specific differences in ARTD1 reduction were observed. The strongest 
tamoxifen-induced ARTD1 reduction was observed in testis, moderately in lung, liver and 
spleen. Notably, the absolute expression of ARTD1 was the highest in liver, moderately in 
testis and lung and the lowest in the spleen. Together these data indicate that a tamoxifen-
inducible Artd1-/- mouse strain was successfully generated. Different layers of complexity can 
account for the observed tissue-specific differences. First, the injected tamoxifen might not 
reach any given target cell in the mouse. Second, translocation of the ERT2 protein into the 
nucleus of the target cell affects the expression of the Cre-recombinase. Lastly, the expressed 
Cre has to assess and recombine the floxed locus on the DNA. Depending on the tissue, the 
chromatin environment of specific loci might vary and influencing Cre recombination 
efficiency. Whether the observed reduction in the individual organs is sufficient to investigate 
phenotypical changes in vivo remains to be investigated. For example, ischemia-reperfusion 
injuries may be a first disease model to determine the functional impact on ARTD1 reduction. 
Next, we assessed Cre-mediated ARTD1 recombination efficiency not only in vivo, but also 
in vitro. To do so, BMDM of either Artd1flox/flox or Rosa26-CreERT2+ Artd1flox/flox mice were 
differentiated for 10 days. On day 5, the culture medium was supplemented with either 20 µM 
4-Hydroxytamoxifen (4-OHT), or vehicle (PBS). Whole cell extracts were generated and 
ARTD1 levels quantified by Western Blot (Figure 17). The quantification of the ARTD1 
levels revealed a successful reduction of ARTD1 in 4-OHT treated Rosa26-CreERT2+ 
Artd1flox/flox BMDM. The ARTD1 levels were below the detection limit, suggesting that the 
recombination of the ARTD1 locus is very efficient if tamoxifen is readily available as is the 
case in vitro.  
*
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Figure 17. Tamoxifen efficiently deletes Artd1 in Rosa26-CreERT2+ Artd1flox/flox BMDM. BMDM 
were differentiated for 10 days. On day 5, the medium was supplemented with 20 µM 
Hydroxytamoxifen (4-OHT) or PBS. Whole cell lysates (150 µg protein) were subjected to Western 
Blot analysis and stained with antibodies against ARTD1 or tubulin. 
3.2. Towards the generation of an ARTD1/2 double knock-out mouse 
As already indicated above Artd1−/−/Artd2−/− double mutant mice are not viable and die at the 
onset of gastrulation, thus demonstrating the crucial role of PARylation during embryonic 
development222. To study the involvement of PARylation during development and adulthood, 
we generated a tamoxifen-inducible Artd1−/− mouse in an Artd2−/− background. Hence, 
tamoxifen administration would induce a partial (see 3.1 and Figure 16) double knock-out in 
vivo. After having successfully combined all three alleles (Rosa26-CreERT2, Artd1flox/flox and 
Artd2−/−) in mice, the animals were administrated 1 mg tamoxifen or vehicle (PBS) for 5 
consecutive days. After another 10 days to allow for recombination and residual ARTD1 to be 
degraded, the mice were viable and did not show any phenotypic abnormalities. Thus, new 
breeding pairs of tamoxifen-treated and vehicle-treated mice were generated. A significantly 
lower reproduction, if any at all, was observed over at least 3 generations in tamoxifen-treated 
mice, compared to normal litter sizes of vehicle treated animals. Additionally, we noticed no 
macroscopic differences of tamoxifen- and vehicle treated animals during aging up to 8 
months. 
 The data suggests, that indeed ARTD1 and ARTD2 are only necessary during 
embryonic development, but dispensable during adulthood under basal conditions. It remains 
very interesting to learn how these animals would behave during different disease models or 
under (genotoxic) stress conditions.  
4-OHT - + - + 
Artd1flox/flox 
Rosa26-CreERT2+ Artd1flox/flox  
+ + 
+ + - - 
- - 
ARTD1 
Tubulin 
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4. Material and methods to unpublished data 
Mice. Artd11-/- mice were generated with support of the Laboratory Animal Service Center 
(LASC) at the University Zürich. Cryopreserved oocytes from Parp11tm1(KOMP)Vlcg mice were 
purchased from the KOMP repository (ID VG12032, www.komp.org, University of 
California Davis). The mice were generated by embryotransfer into a C57BL/6 foster mother 
by the LASC.  
 Tamoxifen-inducible ARTD1 knock-out mice were generated by crossing Artd1flox/flox 
mice with B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj from Jackson Laboratory (Bar Harbor, USA) 
and kindly provided by Rafaela Santoro (University Zürich). Cre recombination was 
performed as described223. Briefly, 1 mg of tamoxifen (Sigma Aldrich) (dissolved in 90% 
cornoil 10% ethanol) or vehicle was administrated intra peritoneal for 5 consecutive days. 
 Artd1/Artd2 double knock out mice were generated by crossing the previously 
generated tamoxifen-inducible Artd1-/- strain to the constitutive Artd2-/- knock-out strain. 
Again, Cre recombination was performed as described above. 
 All animals were housed in pathogen free conditions at the University Zürich. All 
animal experiments were carried out in accordance with the Swiss and EU ethical guidelines 
and have been approved by the local animal experimentation committee of the Canton Zurich 
under licenses 207/2015 and 266/2014. 
 
Cell Culture and reagents. NIH 3T3 and HEK293T cells were cultivated in Dulbecco 
modified Eagle medium (Gibco) supplemented with 10 % fetal calf serum, 5 % 
penicillin/streptamycin. Murine bone marrow derived macrophages (BMDM) were generated 
as previously described224 and maintained in RPMI1640 (Gibco) supplemented with 10 % 
fetal calf serum, 5 % penicillin/streptamycin and 20 ng/ml recombinant murine M-CSF or 
(Preprotech)225. The supplementation 20 µM hydroxytamoxifen (4-OHT) was performed on 
day 5 to induce Cre mediated ARTD1 recombination. Cells were harvested after another 5 
days and ARTD1 expression quantified by Westernblot.  
 Cell culture grade LPS (Escherichia coli O111:B4) was purchased from Sigma-
Aldrich and recombinant murine interferon gamma from Preprotech.   
 
siRNA transfection. siRNA transfection was performed as described earlier78. Briefly, 
Negative-control AllStars (siMOCK) and siRNAs targeting all mouse ARTD family members 
were purchased from Qiagen (Hilden). Cells were seeded and transfected with 20 nmol of 
small interfering RNA (siRNA) per well (in six-well plate) with RNAiMAX Lipofectamine 
(Invitrogen). The experiment was performed 3 days after transfection.  
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Plasmid transfection. Plasmid transfection in HEK293T cells was performed by calcium 
phosphate as described earlier226.The pEGFP-ARTD11 plasmid was provided by P. Chang14. 
 
MACS based NK cell isolation. Splenic NK cells were isolated by using the NK Cell 
Isolation Kit (#130-096-892, Milteneyi Biotech) according to the manufacturer’s protocols. 
Isolated NK cells were maintained in RPMI supplemented with 10 % fetal calf serum, 5 % 
penicillin/streptomycin, 10 ng/ml recombinant murine IL-15 (Preprotech) and 10 mM 
mercaptoethanol (Gibco). The PARP inhibitors Olaparib and Talazoparib were purchased 
from Selleckchem. Recombinant murine IL-12-p70 and IL-18 were purchased from 
Preprotech. 
 
ELISA. IFN-γ cell culture supernatant levels were quantified by Mouse IFN-gamma DuoSet 
ELISA (R&D) according to the manufacturer’s protocols. 
 
Immunofluorescence. Immunofluorescence was performed as described227. The α-p65 
antibody (C-20, Santa Cruz) was diluted 1:250, and DNA was stained in a separate step using 
Hoechst 33258 (Sigma) before mounting.  
 
RNA extraction and quantitative real time PCR (qPCR) analysis. RNA isolation and 
qPCR were performed as described earlier78. Briefly, RNA extraction was performed with the 
NucleoSpin RNA II kit (Macherey-Nagel,). RNA was quantified with a NanoDrop reverse 
transcribed according to the supplier’s protocol (Applied Biosystems).  qPCRs were 
performed with the SYBR green KAPA SYBR® FAST (Sigma-Aldrich) and a Rotor-Gene Q 
2plex HRM system (Qiagen). The relative amounts of each mRNA were normalized to the 
Rps12. 
 
Westernblot. Western Blotting was performed as described227. For Western Blot analysis, 
proteins were separated by SDS- PAGE, and bands were visualized using the Odyssey 
infrared imaging system (LI- COR). Antibodies used for western blotting were anti-
ARTD1/PARP-1 (1:1000, Santa Cruz sc-7150) and anti-Tubulin (1:10,000, Sigma, #T6199). 
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DISCUSSION AND PERSPECTIVES 
1. Summary 
The objective of this thesis was to study ADP-ribosylation during inflammation. The first aim 
addressed ARTD1 function of macrophages in innate immune cells and its contributions 
during inflammation. To identify ARTD1 dependent target genes in macrophages during 
proinflammatory signaling, we performed RNA-sequencing of LPS/IFN-γ stimulated 
Artd1flox/flox and Artd1del/del BMDM. Among others, we identified LPS/IFN-γ-induced Il12b to 
be significantly lower expressed in Artd1del/del BMDMs. We showed that ARTD1 protein but 
not its enzymatic activity contributes to the observed gene expression changes. Il12b encodes 
the p40 subunit of the IL-12p70 cytokine, which is a crucial mediator of lymphocyte 
activation. To study the effect of reduced Il12b expression in vivo we generated a myeloid 
cell specific Artd1-/- strain (Artd1ΔMyel) and tested the stain in three inflammatory models: a) 
acute systemic LPS-induced inflammation, b) local gastric Helicobacter pylori (H.pylori) 
infection and c) a subcutaneous MC-38 tumor model. In all tested models we observed 
reduced lymphocyte activation by decreased IFN-γ expression in Artd1ΔMyel mice compared to 
Artd1flox/flox control animals. In particular we determined decreased NK cell activation during 
sepsis and decreased CD4 and CD8 T cell activation during H.pylori infection as well as the 
MC-38 tumor model. 
 The second aim of this thesis addresses the effect of ADP-ribosylation inhibitors (i.e. 
PARPi). Co-treatment of wild-type mice with LPS and PARPi revealed that even at the tested 
low LPS dose (i.e. 4 mg/kg) the serum levels of different cytokines were reduced 
(unpublished results Figure 2). Moreover, pretreatment of isolated splenocytes from wild-type 
mice phenocopied the reduced expression levels of different cytokines (unpublished results 
Figure 2). Finally, experiments with isolated NK cells in culture, revealed that IL-18-induced 
IFN-γ levels are sensitive to PARPi treatment while IL-12 induced IFN-γ levels were not. 
 The third aim of the thesis addressed the identification of novel ARTD family 
members involved in inflammatory signaling. During a siRNA screen in mouse fibroblasts we 
identified ARTD11 to selectively enhance Cxcl2, Cxcl10 but not Il6 expression. Additionally, 
we observed an ARTD11 nuclear envelope localization, which did not influence nuclear 
translocation of NF-κB. Beside the infertility of homozygous male mice, we did not identify 
macroscopic or histological differences in Artd11-/- mice compared to Artd11+/+ mice.  
2. To be active, or not to be active, that is the question - reoccurring discrepancies 
regarding the involvement of ADP-ribosylation 
How ADP-ribosylation and ARTD1 controls inflammatory gene expression, in particular NF-
κB-induced transcriptional activation is still under debate. Detailed analyses of our lab in 
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macrophages and fibroblasts revealed that ARTD1 regulates NF-κB dependent gene 
expression in an enzymatically independent manner72. ARTD1 serves as a scaffold protein to 
allow physical interaction of p300, the mediator complex and p65/p50 promoting gene 
expression72. In contrast, Martinez-Zamudio et al suggest that LPS-induced ARTD1 histone 
PARylation causes nucleosome remodeling to facilitate NF-κB binding at proinflammatory 
gene promoters75. Recently, a publication confirmed the involvement of ARTD1 for the LPS-
induced Il12b expression in macrophages228. Both, ARTD1 deficient or pharmacologically 
inhibited BMDMs expressed Il12b significantly lower as wild-type control BMDMs. In 
contrast, we identified ARTD1 protein but not its enzymatic activity to regulate Il12b 
expression. While we used the clinically approved PARPi Olaparib which is among the most 
specific ARTD1 inhibitors available, Zhao and colleagues treated BMDMs with the first-
generation PARPi 3-AB228. Studies with 3-AB, the first known PARPi generation, clearly 
provided evidence that this compound has unspecific functions (towards also other enzymes) 
and inhibits multiple ARTD family members148. Hence, other (non)-ADP-ribosylation 
dependent signaling cascades affected by 3-AB might contribute to Il12b repression observed 
by Zhao et al. In fact, STAT-mediated signaling also regulates Il12b expression229. 
Interestingly ARTD8 was shown to MARylate STAT1 antagonizing its phosphorylation and 
decreasing proinflammatory gene expression121. To test whether 3-AB inhibits ARTD8-
mediated STAT1 ADP-ribosylation, in vitro trans-ADP-riboylation assays of ARTD8 and 
STAT1 should be performed. Moreover, to test the functional consequence of 3-AB-
dependent ARTD8 inhibition on LPS-induced Il12b gene expression, siRNA depletion of 
ARTD8 in 3-AB treated BMDM would reveal the contribution of ARTD8. 
 The Il12b gene is a well-studied example that requires chromatin remodeling during 
inflammation-induced gene expression. Studies of the Il12b promoter identified binding sites 
for various transcription factors including NF-κB, C/EBP, AP-1 and NFAT230-232. However 
their binding sites, -30 to -175 bp upstream the transcription start site, are blocked by 
nucleosomes and require nucleosome remodeling prior transcription233. Indeed the 
SWItch/Sucrose Non-Fermentable (SWI-SNF) complex, which is responsible for nucleosome 
positioning234 is recruited to target genes in LPS-stimulated macrophages235. Different models 
describe the targeting of chromatin remodeling machines to their site of action, i.e. acetylated 
histones that target and stabilize the SWI-SNF complex at target loci236. Since ARTD1 
localizes to the Il12b promoter228 and serves as a scaffold protein to facilitate the interaction 
of NF-κB and p30072, it is intriguing to speculate that ARTD1 enhances SWI-SNF binding 
via p300-mediated histone acetylation at distinct gene loci such as Il12b. Chromatin 
immunoprecipitation (ChIP) experiments for SWI-SNF with p300 inhibitor treated ARTD1 
knock-out and wild-type cells during inflammatory signaling could elucidate the proposed 
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model. Ideally, re-ChIP experiments for histone acetylation and SWI-SNF would indicate 
their presence at the same nucleosome.  
Another approach to discriminate ARTD1 adaptor functions from its enzymatically 
dependent functions is the generation of a catalytically dead Artd1 knock-in mouse model. 
Similarly, Schuhwerk et al mutated the amino acid at position 993 from an aspartic acid to an 
alanaine to generate a hypo-PARyating ARTD1 mutant mouse237. CRISPR-Cas9-mediated 
engineering of mouse ES cells and substitution of tyrosine to alanine at position 906 would 
allow the generation of a catalytically deficient Artd1Y906A/Y906A mouse strain. The tyrosine 
residue 906 is located in ARTD1s catalytic domain and essential for NAD+ binding. 
Successful generation of the described strain and testing their phenotype in different 
inflammation models in vivo as well as primary cells in vitro is an exciting approach to 
dissect the different ways ARTD1 is thought to function during inflammatory gene 
expression.  
3. Primary and secondary inflammatory gene expression – Does ARTD1 play a key 
function? 
SWI-SNF-mediated chromatin remodeling helps to differentiate primary and secondary 
inflammatory response genes. Whereas early primary response genes are expressed 
independently of SWI-SNF, late primary and particularly secondary response genes require 
SWI-SNF mediated chromatin remodeling217,238. Potentially, ARTD1 serves as a crucial 
determinant for the expression of secondary response genes, as it was identified to regulate 
Nos2, Il6 and Il1b73,88. Both PARylation and SWI-SNF-dependent chromatin remodeling are 
active processes consuming NAD+ or ATP respectively. Possibly, cells evolved different 
energy-consuming ways of chromatin remodeling to regulate primary and secondary response 
genes. Mechanistically, ARTD1 could render the promoter more accessible by either 
functioning in a SWI-SNF dependent manner as described above, in a PARylation dependent 
mode independently of SWI-SNF or requiring both PARylation and SWI-SNF activity.  
 ARTD1’s function during chromatin remodeling is worthwhile to be addressed 
further. For mechanistic insights it would be essential to determine the genome wide 
occupancy (ChIP-Sequencing) of ARTD1 in macrophages before and after proinflammatory 
stimulation. Furthermore, to gain a global picture on ARTD1 function during inflammation-
induced chromatin remodeling, macrophages could be analyzed by assay for transposase-
accessible chromatin (ATAC)-sequencing239. Comparison of LPS and/or IFN-γ treated 
Artd1wt/wt, Artd1wt/wt + PARPi, Artd1Y906A/Y906A and Artd1del/del macrophages would identify 
distinct loci whose chromatin remodeling are dependent on ARTD1 and PARylation. I 
propose that ARTD1 regulates gene expression in a highly chromatin environment dependent 
manner. The fact that ARTD1 is preferentially localized to nucleosome dense regions18 and 
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that PARylation is a very fast and dynamic process could indicate that cells rely indeed on the 
fast activation of ADP-ribosylation for the remodeling of more heterochromatic regions to 
allow gene expression to take place, particularly during differentiation. In contrast, more 
euchromatic regions such as Il12b would rely on a much slower SWI-SNF dependent 
chromatin remodeling process thus requiring ARTD1 as an adaptor molecule for histone 
acetylation. 
4. ARTD1 in NK cells – an opportunity for PARPi for medication use? 
The synthetically lethal interaction between ARTD1 and BRCA1/2 proteins and the 
development of PARPi is an important therapeutic opportunity for breast and ovarian 
cancers135. Emerging evidences suggest that not only malignancies but also inflammation 
related diseases could benefit from the application of PARPi135. Lately, mainly opinion 
leaders of the field published an appeal for the investigation of PARPi in non-oncological 
diseases150. Sepsis, clinically also known as “systemic inflammatory response syndrome”, is a 
severe infection of mostly bacterial origin240. Sepsis causes a major health-care problem, i.e. 
accounting for 200,000 deaths per year in the United States216. Although significant advances 
in the early implementation of symptomatic care through fluid resuscitation, antibiotic 
therapies and specific organ support techniques have been established, these strategies 
unfortunately did not reduce mortality in severe septic patients216. In addition, increasing 
microbial resistances and the slow development of new antimicrobial agents require new 
therapeutic approaches to treat this deadly disease216. Both PARPi administration or genetic 
deficiency of ARTD1 rendered mice significantly more resistant towards sepsis induced by 
intraperitoneal LPS injection89,166 or cecal ligation puncture (CLP)165. The protective PARPi 
effect has not been linked to a particular cell type and it is currently not known whether the 
observed effects are directly mediated by ARTD1 or indirectly (e.g. by transcriptional 
activation of another ARTD family member).  
 In this thesis we discovered, that not macrophages, but NK cell are sensitive to 
PARPi during their IL-18 mediated activation (unpublished data Figure 8). PARPi treated 
MACS isolated murine NK cells expressed significantly lower levels of IFN-γ than their 
untreated control counterparts. NK-cell type regulated processes might thus be a promising 
cell type to be treated with PARPi. These include non-oncological disease models such as 
sepsis, arteriosclerosis, graft versus host disease and diabetes where NK cell activation is 
augmenting disease progression215. 
While research has extensively focused on the roles of macrophages, neutrophils and 
conventional T lymphocytes during sepsis, only lately the roles of natural killer cells have 
been increasingly appreciated216. Systemic administration of monoclonal anti-NK1.1 or 
polyclonal antiasialo GM1 antibodies in mice significantly reduce NK cell numbers in vivo241. 
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In a CLP model, mice treated with anti-asialo-GM1 were protected against CLP-induced 
mortality compared to IgG-treated controls242. Moreover these animals are significantly 
protected against LPS-induced shock characterized by significantly reduced cytokine levels 
(i.e. IFN-γ and TNF-α). It is well appreciated that during CLP-induced shock, NK cells 
migrate from blood and spleen to the inflamed peritoneal cavity where they amplify the 
proinflammatory activities of the myeloid cell population. It is thus intriguing to speculate 
that the known anti-inflammatory PARPi effect during sepsis would (a) dampen NK-cell 
mediated IFN-γ expression, (b) interfere with their amplification role and (c) reduce the 
inflammatory burden of the host. NK cell specific Artd1-/- mice are proposed to be protected 
against sepsis by reduced IFN-γ levels. Thus, their investigation in the above-mentioned 
disease models would be interesting. 
5. Cellular high-resolution analysis of ARTD1 in vivo- A new era to study ADP-
ribosylation? 
Since the discovery of ARTD1 in 1963243, the field went through different phases and 
fascinating contributions to our understanding of ADP-ribosylation43. The phase involved 
biochemical characterization of the purified writers (i.e. ARTD1) and the erasers (i.e. PARG) 
as well as dynamics of PAR levels in living cells. The second phase comprised the 
development of the first generation of PARP inhibitors and their contribution to DNA damage 
induced cytotoxicity in tumor cells23. The establishment of todays routine molecular 
methodologies allowed the cloning of ARTD1 cDNA during the third phase, which 
revolutionized the field for the first time. From here on the field of ADP-ribosylation evolved 
and expanded during a fourth phase by many exciting advances such as the crystallographic 
structure analyses of ARTD proteins and domains, a comprehensive coverage of all ART 
family members and the identification of PAR-binding motifs. Any of the described 
evolutions in ADP-ribosylation biology started with ARTD1 and ADP-ribosylation remains 
mainly associated with various kinds of cellular stress and pathological conditions. Although 
we learned a lot from cell based systems, they are very limited in their utility to study 
complex cellular interactions that regulated all diseases. Functional studies of ARTD1 in vivo 
has so far only been possible by the whole body knock-out mouse models221,244,245. I thus 
propose a new -fifth- phase of ADP-ribosylation biology by generating and studying tissue 
specific knock-out animals which allow high resolution in vivo studies of writers, readers or 
erasers of ADP-ribosylation. In this thesis we present the pioneering work of a conditional 
and myeloid cell type specific Artd1-/- mouse and its utility to confirm and extent the complex 
aspects of ARTD1 during immunity in a particular cell type. Especially for immunological 
aspects in vivo mouse models are essential to understand the complex cellular interactions. 
The ability to apply the generated “floxed” Artd1 mouse strain is only limited by the 
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availability of suitable Cre-expressing mouse lines and the disease models246. The immune 
system is very powerful as it can very efficiently eliminate foreign material, but also host 
cells. CD4 T cells are important cells to balance pro- and anti-inflammatory actions, as they 
differentiate into T helper cells or Treg cells. Treg cells suppress proinflammatory Th1 and 
Th17 immune reponses107. Studies of the classical whole body ARTD1 knock-out animals 
revealed increased numbers of Treg cells as compared to wild type littermates111. To date we 
cannot address whether increased Treg cell number in Artd1-/- mice is a direct intrinsic or an 
indirect extrinsic driven process, but it would be very interesting to address these questions 
and their physiological relevance in more detail by generating a CD4 T cell specific ARTD1 
knock-out mouse. 
 Additionally, since our knowledge about other ART superfamily members247 
significantly increased over the past years it is very exciting to expand the collection of tissue 
specific knock-out models beyond ARTD1 to learn and prepare the field for the next phase of 
ADP-ribosylation biology. 
6. ARTD11 – The nuclear bouncer: You`re in or out!  
The knowledge about ARTD11 is very limited: It plays at the animal level an essential role 
during spermatogenesis and its absence renders Artd11-/- mice infertile220. At the cellular 
level, ARTD11 localizes to the nuclear envelope220. Another study overexpressed a 
genetically manipulated ARTD11 in cells and discovered potential ARTD11 MARylated 
target proteins mainly involved in RNA transport248. In our study we identified ARTD11 to 
selectively enhance Cxcl2 and Cxcl10 expression but not Il6 (unpublished data Figure 5). The 
formation of messenger ribonucleoprotein particels (mRNPs) is an essential step for mRNA 
export through the nuclear pore complex into the cytoplasm. Based on our studies and the 
published data, it is tempting to propose that ARTD11 selectively regulates nuclear RNA 
exports in a MARylation dependent manner of only a subset of inflammatory cytokine 
mRNAs. Mechanistically, ARTD11 could modify either nuclear pore complex molecules or 
mRNPs to promote mRNP transport. Retained mRNAs are directly degraded and thus not 
detectable by qPCR. To further investigate ARTD11 function, nuclear-cytolosic fractionation 
and subsequent proinflammatory cytokine mRNA quantification in both compartments would 
identify faulty nuclear mRNA export. Alternatively, RNA fluorescence in situ hybridization 
(RNA FISH) mediated quantification and localization analyses could also strengthen the 
proposed model. Additionally, specific ARTD11 inhibitor development would allow the 
dissection of an enzymatically dependent and an enzymatically independent phenotype.  
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ABBREVIATIONS 
3-AB 3-aminobenzamide 
4-OHT 4-Hydroxytamoxifen 
AA Aminoacids 
AIF Apoptosis-inducing factor 
Arg Argine 
ARTC ADP-ribosyltransferase C2/C3 cholera toxin-like  
ARTD ADP-ribosyltransferase diphtheria toxin like  
ARTs ADP-ribosyltransferase  
ATP Adnosine triphosphate 
BER Base excision repair 
BMDM Bone marrow derived macrophages 
CBP CREB-binding protein 
ChIP Chromatin immunoprecipitation  
CLP Cecal ligation uncture 
CSF2  Colony stimmulating factor 
DAMPs Danger associated molecular pattern 
DDR DNA damage response 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid¨ 
DNBS Dinitrobenzene sulfonic acid 
DP  Double posistive 
DSB Double strand break 
DSS Dextran sulfate sodium 
DTX3L Deltex E3 ubiquitin ligase 3L 
ELISA Enzyme-linked immunosorbent assay  
FoxP3 Forkhead box P3 
GFP Green fluorescent protein 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HDAC2 Histone Deacetylase 
HEK293T Human embryonic kidney cells 
HIV-1 Human immunodeficiency virus 
HMGB1 High mobility group box 1 protein 
HNP  Human neutrophil peptide 
HR Homologous recombination  
hr Hour 
HuR Human antigen R 
IBD Inflammatory bowel disease  
IFN-γ Interferon gamma 
Ig Immunoglobulin 
IL-12,  Interlekin 12 
IL-18 Interlekin 18 
IL-1β Interlekin 1 beta 
Il-23 Interlekin 23 
IL-6 Interleukin 6 
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ILC Innate lymphoid cell 
ISG Interferon-stimulated gene 
kDa Kilo dalton 
LIF Leukemia inhibitory factor 
Lys Lysine 
MACS Magnetic-activated cell sorting 
MARylation Mono-ADP-ribosylation 
MCAO Middle cerebral artery occlusion 
MEF Mouse embryonic fibrobasts 
Mins Minutes 
miRNA Micro RNA 
ml Milliliter 
MLF Mouse lung fibroblast 
mRNPs Messenger ribonucleoprotein particels 
NAD Nicotinamide adenine dinucleotide 
NEMO NF-kB essential modulator  
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NFAT Nuclear factor of activated T-cells 
NK cells Natural killer cells 
nNOS Neuronal nitric oxide synthase 
NOS Nitric oxide 
p300 E1A binding protein p300 
p38MAPK Mitogen-activated protein kinase 3 
PAAN Parthanatos AIF-associated nuclease 
PARG  Poly-ADP-ribose glycohydrolase  
PARPi PARP inhibitors 
PARylation Poly-ADP-ribosylation 
PBS Phosphate buffered saline 
PD Parkinson`s disease  
PLC-γ Phospholipase C-γ 
PTM Posttranslational modification 
qRT-PCR Quantitative real-time PCR 
RA Rheumatoid Arthritis 
RAGE Receptor for advanced glycation endproducts 
RISC RNA-induced silencing complex 
RNA FISH RNA fluorescence in situ hybridization 
RNS Reactive nitrogen species 
ROS Reactive oxygen species  
rRNA Ribosomal RNA 
STAT Signal transducer and activator of transcription 
SWI-SNF SWItch/Sucrose Non-Fermentable  
TCR T cell receptor 
TF Transcription factor 
TGF Tranforming groth factor 
TGFbR Tranforming groth factor receptor 
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TNF-α Tumor necrosis factor alpha  
TRAF Tumour-necrosis factor receptor-associated factor 
µg Microgramm 
VEEV Venezuelan equine encephalitis virus 
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